CLINICAL STUDY PROTOCOL 
A Phase 2b, Multi-Center, Placebo-Controlled, Randomized Study of 
BPZE1 Intranasal Pertussis Vaccine in Healthy Adults to Assess the 
Immunological Response and Safety Profile of Single Dose (Prime) and 
Two Doses (Prime + Boost) Schedule, and Compared to a Boostrix™ Prime 
Dose With or Without a BPZE1 Boost Dose 
IB-200P 
Sponsor: 
Sponsor Contact: 
Medical Monitor: 
Date of Original Protocol: 
Date of Amendment 1: 
Date of Amendment 2: 
Date of Amendment 3: 
Date of Amendment 4: 
Date of Amendment 5: ILiAD Biotechnologies 
4581 Weston Road, Suite 260 
Weston, FL 33331 
Chief Operating Officer 
Medical Monitor 
04 January 2018 (Version 1.0) 
06 March 2019 (Version 2.0) 
17 April 2019 (Version 3.0) 
15 May 2019 (Version 4.0) 
31 May 2019 (Version 5.0) 
20 November 2019 (Version 6.0) 
CONFIDENTIAL  
All financial and nonfinancial support for this study will be provided by ILiAD 
Biotechnologies. The concepts and information contained in this document or generated 
during the study are considered proprietary and may not be disclosed in whole or in part 
without the expressed, written consent of ILiAD Biotechnologies. 
The study will be conducted according to the International Council for Harmonisation 
harmonised tripartite guideline E6(R2): Good Clinical Practice.  
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendment 5 
Confidential Page 6 Table of Contents 
Table of Contents ....................................................................................................................... 6
List of Tables ..................................... ....................................................................................... 10
Protocol Synopsis................................... .................................................................................. 11
List of Abbreviations............................... ................................................................................. 27
1 Introduction ....................................... ............................................................................... 29
1.1 Background Information ......................................................................................... 29
1.2 Rationale ................................................................................................................. 31
1.3 Potential Risks and Benefits ................................................................................... 32
1.3.1 Potential Risks .................................... ..................................................... 32
1.3.2 Risks of Study Participation ....................... ............................................. 33
1.3.3 BPZE1 Risks to Study Subjects ...................... ......................................... 33
1.3.4 Risks to the Environment or Potential for Interactio n With Wild-Type B. 
Pertussis  Strains ....................................................................................... 34
1.3.5 Boostrix Risks to Study Subjects ................... .......................................... 36
1.3.6 Known Potential Benefits ........................... ............................................. 37
2 Study Objectives and Endpoints ..................... ................................................................. 38
2.1 Primary Objectives.................................................................................................. 38
2.1.1 Primary Immunogenicity Objective.................... ..................................... 38
2.1.2 Primary Safety Objective ........................... .............................................. 38
2.2 Secondary Objectives.............................................................................................. 38
2.2.1 Secondary Immunogenicity Objectives ................ ................................... 38
2.2.2 Secondary Colonization Objectives .................. ....................................... 39
2.2.3 Secondary Safety Objectives ........................ ........................................... 39
2.3 Exploratory Objective ............................................................................................. 39
2.4 Primary Endpoints .................................................................................................. 39
2.4.1 Primary Immunogenicity Endpoints ................... ..................................... 39
2.4.2 Primary Safety Endpoints ........................... ............................................. 40
2.5 Secondary Endpoints .............................................................................................. 40
2.5.1 Secondary Systemic Immunogenicity Endpoints ........ ............................ 40
2.5.2 Secondary Mucosal Immunogenicity Endpoints ......... ............................ 42
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendment 5 
Confidential Page 7 2.5.3 Secondary Colonization Endpoints ................... ....................................... 43
2.5.4 Secondary Safety Endpoints ......................... ........................................... 44
2.6 Exploratory Endpoint ............................... ............................................................... 44
3 Investigational Plan ............................... ........................................................................... 45
3.1 Study Design ....................................... .................................................................... 45
3.1.1  Rationale of Study Design ....................................................................... 48
4 Subject Selection and Withdrawal Criteria .......... ............................................................ 50
4.1 Selection of Study Population ...................... ........................................................... 50
4.1.1  Inclusion Criteria ..................................................................................... 50
4.1.2  Exclusion Criteria .................................................................................... 51
4.2 Withdrawal of Subjects From Study Treatment and/or t he Study .......................... 54
4.2.1  Reasons for Withdrawal/Discontinuation ................................................ 54
4.2.2  Handling of Withdrawals ......................................................................... 55
4.2.3  Replacements ........................................................................................... 56
5 Study Treatments ................................... ........................................................................... 56
5.1 Method of Assigning Subjects to Treatment Groups .............................................. 56
5.2 Treatments Administered ........................................................................................ 57
5.3 Identity of Investigational Product.......................................................................... 58
5.3.1 Study Drug Packaging and Storage ................... ...................................... 59
5.3.2 Investigational Product Accountability ............. ....................................... 60
5.3.3 Other Supplies...................................... .................................................... 60
5.4 Overdose Management ................................ ........................................................... 61
5.4.1  Treatment of Overdose ............................................................................ 61
5.5 Blinding............................................ ....................................................................... 61
5.5.1 Breaking the Blind Due to Medical Emergency ........ .............................. 62
5.6 Treatment Compliance ............................... ............................................................. 62
5.7 Prior Vaccinations and Concomitant Therapy ......... ............................................... 62
6 Study Assessments and Procedures ................... ............................................................... 64
6.1 Demographic and Baseline Data ...................... ....................................................... 64
6.2 Medical History .................................... .................................................................. 64
6.2.1  Concomitant Medication.......................................................................... 64
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendment 5 
Confidential Page 8 6.3 Safety Assessments ................................................................................................. 65
6.3.1 Vital Sign Measurements ............................ ............................................. 65
6.3.2 Post-vaccination Evaluation ........................ ............................................ 65
6.3.3 Complete Physical Examination ...................... ........................................ 66
6.3.4 Clinical Safety Laboratory Tests ................... ........................................... 66
6.3.4.1 Serology ........................................... ........................................................ 67
6.3.4.2 Urine Drug Screen .................................. ................................................. 67
6.3.4.3 Urine Pregnancy Test ............................... ................................................ 67
6.3.5 Adverse Events ..................................... ................................................... 68
6.3.5.1 Definitions of Adverse Events ...................... ........................................... 68
6.3.5.2 Serious Adverse Events ............................. .............................................. 68
6.3.5.3 Site-Specific and General Systemic Reactogenicity Sy mptoms.............. 68
6.3.5.4 Assessing and Documenting Adverse Events ........... ............................... 71
6.3.5.5 Reporting Adverse Events ........................... ............................................ 72
6.3.5.6 Reporting Serious Adverse Events ................... ....................................... 73
6.3.5.7 Suspected Unexpected Serious Adverse Reactions and N onserious 
Adverse Events of Special Interest .......................................................... 73
6.3.5.8 Assessment of Severity ............................. ............................................... 74
6.3.5.9 Assessment of Causality ............................ .............................................. 74
6.3.5.10  Follow-up of Subjects Reporting Adverse Events ................................... 75
6.3.6 Immunogenicity Assessments ......................... ......................................... 75
6.4 Halting Rules ...................................... .................................................................... 76
6.5 Pregnancy .......................................... ...................................................................... 77
6.6 Laboratory Analyses ................................ ............................................................... 77
6.7 Sample Collections ................................. ................................................................ 78
7 Statistical and Analytical Plan .................... ...................................................................... 79
7.1 Primary Immunogenicity and Safety Endpoints ........ ............................................. 79
7.2 Secondary Immunogenicity and Safety Endpoints ...... ........................................... 80
7.3 Exploratory Endpoints .............................. .............................................................. 84
7.4 Sample Size Calculations ........................... ............................................................. 84
7.5 Analysis Sets ...................................... ..................................................................... 85
7.6 Description of Subgroups to be Analyzed ............ .................................................. 86
7.7 Statistical Analysis Methodology ................... ........................................................ 86
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendment 5 
Confidential Page 9 7.7.1 Analysis of Primary Immunogenicity Endpoint ........ .............................. 87
7.7.2 Analysis of Primary Safety Endpoint ................ ...................................... 88
7.7.3 Analysis of Secondary Immunogenicity Endpoint ...... ............................ 88
7.7.4 Analyses of Efficacy Endpoint ...................... .......................................... 89
7.7.5 Analysis of Secondary Safety Endpoints ............. .................................... 89
7.7.6 Other Analyses ..................................... .................................................... 90
7.7.7 Interim Analyses ................................... ................................................... 90
8 Data Quality Assurance ............................. ....................................................................... 91
8.1 Data Management .................................... ............................................................... 91
9 Ethics ............................................. ................................................................................... 92
9.1 Institutional Review Board ......................... ............................................................ 92
9.2 Ethical Conduct of the Study ....................... ........................................................... 92
9.3 Subject Information and Consent..................... ....................................................... 92
10 Investigator’s Obligations ................................................................................................ 94
10.1  Confidentiality ........................................................................................................ 94
10.2  Financial Disclosure and Obligations ..................................................................... 94
10.3  Investigator Documentation .................................................................................... 95
10.4  Study Conduct ......................................................................................................... 96
10.5  Adherence to Protocol............................................................................................. 96
10.6  Adverse Events and Study Report Requirements ................................................... 96
10.7  Investigator’s Final Report ..................................................................................... 96
10.8  Records Retention ................................................................................................... 96
10.9  Publications ............................................................................................................. 97
11 Study Management ........................................................................................................... 98
11.1  Monitoring .............................................................................................................. 98
11.1.1 External Data Monitoring Committee ................. .................................... 98
11.1.1.1  Safety Monitoring Committee ................................................................. 98
11.1.2 Monitoring of the Study ............................ ............................................... 99
11.1.3 Inspection of Records .............................. ................................................ 99
11.2  Management of Protocol Amendments and Deviations........................................ 100
11.2.1 Modification of the Protocol ....................... ........................................... 100
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendment 5 
Confidential Page 10 11.2.2 Protocol Deviations................................. ............................................... 100
11.3  Study Termination ................................................................................................. 101
11.4  Final Report .......................................................................................................... 101
12 Reference List................................................................................................................. 102
13 Appendices ..................................................................................................................... 104
13.1  Appendix: Schedule of Events .............................................................................. 104
13.2  Appendix: FDA Table for Laboratory Grading ..................................................... 108
13.3  Appendix: FDA Table for Vital Sign Grading ...................................................... 110
List of Tables 
Table 3-1 Dosing Scheme ...................................... ......................................................... 45
Table 3-2 Dosing and Safety Lead-In Cohort ................... .............................................. 47
Table 6-1 Toxicity Grading Scales ............................ ...................................................... 69
Table 7-1 95% Confidence Interval and Width for Selected Respo nse Rate Assumptions 
for Relevant Treatment Arm Sample Sizes ..................................................... 85
Table 13-1 Schedule of Events ................................. ....................................................... 105
Table 13-2 Laboratory Abnormalities ........................... .................................................. 108
Table 13-3 Vital Sign Abnormality ............................. .....................................................110
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendment 5 
Confidential Page 11 Protocol Synopsis 
Protocol 
Number: IB-200P 
Title: A Phase 2b, Multi-Center, Placebo-Controlled, Randomized Study of 
BPZE1 Intranasal Pertussis Vaccine in Healthy Adults to Assess the 
Immunological Response and Safety Profile of Single Dose (Prime) and 
Two Doses (Prime + Boost) Schedule, and Compared to a Boostrix™ 
Prime Dose With or Without a BPZE1 Boost Dose 
Sponsor: ILiAD Biotechnologies 
4581 Weston Road, Suite 260 
Weston, FL 33331 
Study Phase: 2b 
Study Sites: 3 to 5 clinical sites in the United States 
Indication: Pertussis in adults and adolescents 
Rationale: The availability of a cost-effective pertussis vaccine that provides 
improved efficacy and prolonged protection with the potential to reduce 
or eliminate transmission would present a breakthrough in the 
prevention of colonizing pertussis infections. This novel approach may 
not only protect BPZE1-vaccinated individuals from Bordetella 
pertussis  infection but may also reduce the B. pertussis reservoir in the 
adult population. The ability to prevent colonization by wild type B. 
pertussis  that enable transmission may facilitate substantial reduction in 
the incidence of pertussis in infants. 
The intranasally administered BPZE1 vaccine provides an opportunity 
to generate a locally effective mucosal antibody response at the site of 
potential exposure, and thereby mimics the route of entry of the wild 
type pathogen and results in a broader immune response (type 1 T helper 
cells, type 2 T helper cells, and nasal mucosal immune responses). The 
study population, healthy adults, has been chosen to maximize the 
quality of immunogenicity data while minimizing risk and potential 
safety signals.  
We hypothesize that the BPZE1 vaccine will be safe and induce nasal 
mucosal immunity beyond that observed with standard vaccination with 
Boostrix™ and that BPZE1 will also induce systemic immunity. 
Immunity will be measured in enzyme-linked immunosorbent assays 
(ELISA) specific for pertussis toxin (PT), filamentous hemagglutinin 
(FHA), pertactin (PRN), and fimbriae (FIM) 2/3, and a broader pertussis 
ELISA developed with BPZE1 whole cell extract. In addition, we 
hypothesi ze that a priming dose of intranasal BPZE1 vaccine will result 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendment 5 
Confidential Page 12 in fewer subjects colonized (eg, lower colony counts) following a 
boosting dose of BPZE1, whereas a priming dose of Boostrix will not 
reduce colonization following a boosting dose of BPZE1, ie, Boostrix 
will generate less nasal mucosal immunity to prevent colonization by the 
BPZE1 live attenuated B. pertussis  strain. Lastly, given that the majority 
of the population has received pertussis vaccination on multiple 
occasions, this study will assess the safety and immune response of 
BPZE1 as booster delivered after a prime dose of Boostrix in an adult 
population. 
Objectives: Primary objectives 
Immunogenicity: 
To assess nasal mucosal secretion immune response (secretory
immunoglobulin A [S-IgA]) following intranasal vaccination with
BPZE1 (109 colony-forming units [CFU]) when used as a single
(eg, prime) or 2-dose (eg, prime + boost) series.
Safety 
To assess reactogenicity (all) and specific safety laboratory
parameters (safety lead-in cohort only) following intranasal
vaccination with BPZE1, either 107 CFU (safety lead-in cohort
only) or 109 CFU (safety lead-in cohort and full cohort), in healthy
adults.
Secondary Objectives 
Immunogenicity: 
To assess the systemic immune response (immunoglobulin G [IgG],
immunoglobulin A [IgA]) following intranasal vaccination with
BPZE1 when used as a single (eg, prime) or 2-dose (eg, prime +
boost) series.
To assess nasal mucosal secretion (S-IgA) and systemic (IgG, IgA)
immune response following intranasal vaccination with BPZE1
boost dose proceeded by Boostrix or BPZE1 prime dose.
To assess nasal mucosal secretion (S-IgA) and systemic (IgG, IgA)
immune response through 9 months after a single (eg, prime) dose
and 6 months after a 2-dose series (eg, prime + boost), where the
prime dose is BPZE1 or Boostrix, and BPZE1 (or placebo) is the
boost dose.
To assess nasal mucosal secretion (S-IgA) and systemic (IgG, IgA)
immune response following immunization with BPZE1 or Boostrix
prime dose, with or without a BPZE1 boost dose, in relation to
baseline immunity status (positive [Yes/No]) of pertussis antibodies
PT, PRN, FHA, and FIM 2/3.
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendment 5 
Confidential Page 13 Colonization: 
To assess nasopharyngeal colonization or clearance of BPZE1 in
either a prime or prime + boost strategy, and in relationship to
vaccination strategies with Boostrix.
Safety: 
To describe (severity and clinical significance) of vaccine-related
adverse events (AEs) following a single or 2-series intranasal
vaccination (prime or prime + boost) with BPZE1 or Boostrix
prime dose with or without a BPZE1 boost dose.
To describe all serious AEs during the study.
Exploratory Objective
To examine cell-mediated (eg, B cell, CD4 T lymphocytes + T cell,
CD8T lymphocytes + T cell) responses in a subset of no more than
60 subjects using peripheral blood mononuclear cells to be
collected at baseline and 8 days post-vaccination (prime and boost).
This subset will be from the randomized cohort population of 109
C
FU BPZE1 only.
To further characterize nasal mucosal secretion and serum
immunological responses across time, relative to baseline status and
relative to vaccination response, with the current assays and with
any future assays developed for BPZE1.
Primary Endpoints: 
Immunogenicity: 
Mucosal seroconversion (nasal mucosal secretion sampling) :
Proportion of subjects who achieve seroconversion against at least
1 pertussis antigen (PT, FHA, PRN, FIM 2/3, or BPZE1 whole cell
extract)  in nasal secretions on Day 29 or 113 (prime or prime +
boost).
Mucosal seroconversion is defined as a 2-fold increase over the
baseline value (collected during screening) or a 4-fold increase over
the minimal limit of assay detection (whenever the baseline value
falls below the limits of assay detection) for any of the
pertussis-specific antibodies (S-IgA ELISA): PT, FHA, PRN, FIM
2/3, BPZE1 whole cell extract. Seroconversion will be calculated
based on absolute titer response over baseline and  by standardizing
pertussis specific ELISA responses relative to non-pertussis specific
total mucosal secretion (eg, IgA). To be further defined during
assay development and within the statistical analysis plan.
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendment 5 
Confidential Page 14 Mucosal baseline samples will be taken at the screening visit. 
Safety: 
Solicited AEs (local, nasal/respiratory, and systemic reactogenicity
events) for 7 days following each vaccination by severity score,
duration, and peak intensity. Local reactogenicity will only be
monitored following the intramuscular (IM) vaccination.
Safety laboratory results (serum chemistry, hematology,
coagulation) by US Food and Drug Administration (FDA) toxicity
score (change from baseline or absolute toxicity score) in the safety
lead-in cohort at Day 8 following each vaccination. In the case of
no toxicity classification the score of 0 will be assigned.
Secondary Endpoints: 
Systemic Immunogenicity (serum sampling)  expressed separately for 
IgG, IgA, and IgG or IgA ELISA when possible:  
Proportion of subjects who achieve seroconversion against pertussis
antigen (PT, FHA, PRN, FIM 2/3, or BPZE1 whole cell extract)
over baseline for.
At least 1 antigen on each  of the Days 29, 85, 113, 169, or 254
At least 1 antigen on any  of the Days 29, 85, 113, 169, or 254
At least any 1  antigen on all  Days 29, 85, 113, 169, or 254
Systemic seroconversion is defined as a 2-fold increase over the 
baseline value or a 4-fold increase over the minimal limit of assay 
detection (whenever the baseline value falls below the limits of 
assay detection). Both IgG and IgA ELISA will measure antibodies 
against the following pertussis-specific antigens of PT, FHA, PRN, 
FIM 2/3, and IgG ELISA will measure antibodies against broader 
pertussis-specific antigens in BPZE1 whole cell extract. 
Serum baseline samples will be taken at Day 1 prior to vaccination. 
Proportion of subjects who achieve seroconversion (IgG ELISA
only) against BPZE1 whole cell extract over baseline:
On either  Day 29 (prime) or 113 (boost)
On both  Days 29 (prime) and 113 (boost).
Proportion of subjects who achieve seroconversion against the
acellular pertussis (aP) antigens PT, FHA, and PRN over baseline:
On either  Day 29 (prime) or 113 (boost)
On both  Days 29 (prime) or 113 (boost).
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendment 5 
Confidential Page 15 Proportion of subjects who achieve seroconversion against 2 or
more pertussis antigens (PT, FHA, PRN, FIM 2/3, and BPZE1
whole cell extract) over baseline:
On each  of the Days 29, 85, 113, 169, or 254
On any  of the Days 29, 85, 113, 169, or 254
At least the same 2 antigens  on all  Days 29, 85, 113, 169, and
254.
Proportion of subjects who demonstrate boosting for each pertussis
antigen (PT, FHA, PRN, FIM 2/3, and BPZE1 whole cell extract)
on Day 113. Boost is defined as at least a 2-fold increase from the
pre-boost sample taken on Day 85.
The Geometric Mean Fold Rise against each pertussis antigen (PT,
FHA, PRN, FIM 2/3, and BPZE1 whole cell extract):
On Days 29, 85, 113, 169, and 254 over baseline  (Day 1)
On Days 113, 169, and 254 over pre-boost  (Day 85)
The maximum over baseline  on either Day 29 or 85
(post-priming response)
The maximum over pre-boost  (Day 85) on any of the
Days 113, 169, or 254 (post-boost response)
The maximum during  the study.
The Geometric Mean Titer against each pertussis antigen (PT, FHA,
PRN, FIM 2/3, and BPZE1 whole cell extract):
On Days 29, 85, 113, 169, and 254
The maximum on Day 29 or 85 ( after priming  dose)
The maximum after Days 113, 169, or 254 ( after boosting
dose)
The maximum during  the study.
Mucosal Immunogenicity S-IgA ELISA (nasal mucosal secretion 
sampling):  
Proportion of subjects who achieve seroconversion against any
pertussis-specific antigen (PT, PRN, FHA, FIM 2/3, or BPZE1
whole cell extract) over baseline:
At least 1 antigen on each  of the Days 29, 78, 113, 169, or 254
At least 1 antigen on any  of the Days 29, 78, 113, 169, or 254
At least any  1 antigen on all Days 29, 78, 113, 169, and 254.
Proportion of subjects who achieve seroconversion against BPZE1
whole cell extract over baseline:
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendment 5 
Confidential Page 16 On either  Day 29 (prime) or 113 (boost)
On both  Days 29 (prime) and 113 (boost).
Proportion of subjects who achieve seroconversion against aP
antigens PT, FHA, and PRN over baseline:
On either  Days 29 (prime) or 113 (boost)
On both  Days 29 (prime) and 113 (boost)
Proportion of subjects who achieve seroconversion for any 2 or
more pertussis antigens (PT, PRN, FHA, or BPZE1 whole cell
extract) over baseline:
On each  of Days 29, 78, 113, 169, or 254
On any  of Days 29, 78, 113, 169, or 254
At least the same 2 antigens  on all  Days 29, 78, 113, 169, and
254
Proportion of subjects who demonstrate boosting against each
pertussis antigen (PT, FHA, PRN, FIM 2/3, and BPZE1 whole cell
extract) on Day 113. Boost is defined as at least a 2-fold increase
from pre-boost sample taken at Day 78.
The Geometric Mean Fold Rise against each pertussis antigen (PT,
FHA, PRN, FIM 2/3, and BPZE1 whole cell extract):
On Days 29, 78, 113, 169, and 254 over baseline  (Day 1)
On Days 113, 169, and 254 over pre-boost  (Day 78)
The maximum over baseline  on either Day 29 or 78
(post-priming response)
The maximum over pre-boost  (Day 78) on any of the
Days 113, 169, or 254 (post-boost response)
The maximum during  the study.
The Geometric Mean Titer against each pertussis antigen (PT, FHA,
PRN, FIM 2/3, and BPZE1 whole cell extract):
On Days 29, 78, 113, 169, and 254
The maximum on Days 29 or 78 ( after priming  dose)
The maximum after Days 113, 169, or 254 ( after boosting
dose)
The maximum during  the study.
Colonization: 
Proportion of subjects with positive B. pertussis  by bacterial culture
of nasal sample on each day and on any of Days 92, 96, and 113.
B. pertussis  colony counts on each day (Days 92, 96, and 113).
Number of subjects who remain culture positive for B. pertussis  at
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendment 5 
Confidential Page 17 Days 78 (following priming) and 254 (following boost). 
Safety: 
Unsolicited AEs (eg, treatment-emergent AEs, serious AEs, and
suspected unexpected serious adverse reactions) collected for
28 days following each vaccination by Medical Dictionary for
Regulatory Activities (MedDRA) classification and severity score.
Unsolicited AEs related to vaccination through Day 113 by
MedDRA classification and severity score.
Serious AEs through 6 months following the last vaccination (or
until resolved or stable) by MedDRA classification, relatedness, and
severity score.
Vital sign measurements with severity scoring immediately
following vaccination.
Exploratory Endpoint: 
Cell-mediated (eg, B cell, CD4 T lymphocytes + T cell, CD8 T
lymphocytes + T cell) responses (eg, cell staining, cytokine
production) following stimulation of peripheral blood mononuclear
cells collected at baseline, and 8 days post-vaccination (prime and
boost) to pertussis-specific antigens. Results expressed both as
absolute values and fold over baseline (per specific assay
characteristics).
Following the outcomes of the primary and second analyses,
additional exploratory endpoints may be tested for systemic or nasal
mucosal immunogenicity (IgG or IgA) responses at any time point
collected and not already performed in the primary or secondary
analysis sets.
The Geometric Mean Titer, expressed for serum IgG ELISA against
tetanus and diphtheria on Days 29 and 113.
Study 
Population: Inclusion Criteria 
Each subject must meet all the following criteria to be enrolled in this 
study: 
1. Is a male or nonpregnant female 18 to 50 years of age, inclusive, on
Day 1 (primary vaccination).
2. Is capable of understanding the written informed consent, provides
signed and witnessed written informed consent, and agrees to
comply with protocol requirements.
3. Female subjects must be nonpregnant and nonlactating and meet
1 of the following criteria:
a)Postmenopausal (defined as 12  consecutive months with no
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendment 5 
Confidential Page 18 menses without an alternative medical cause or documented 
plasma follicle-stimulating hormone level in the postmenopausal 
range); 
b) Surgically sterile (ie, hysterectomy, bilateral tubal ligation, or
bilateral oophorectomy).
NOTE: These procedures and laboratory test results must be 
confirmed by physical examination, or by subject recall of specific 
date and hospital/facility of procedure, or by medical documentation 
of said procedure. 
c) Is of childbearing potential (defined as any female who has
experienced menarche and who is NOT permanently sterile or
postmenopausal), agrees to be heterosexually inactive from at
least 21 days prior to enrollment and through 3 months after the
boosting vaccination or agrees to consistently use any of the
following methods of contraception from at least 21 days prior
to enrollment and through 3 months after the boosting
vaccination:
i. Condoms (male or female) with spermicide
ii. Diaphragm with spermicide
iii. Cervical cap with spermicide
iv. Intrauterine device
v. Oral or patch contraceptives
vi. Norplant®, Depo-Provera®, or other FDA-approved
contraceptive method that is designed to protect against
pregnancy.
NOTE: Periodic abstinence (eg, calendar, ovulation, symptothermal, 
post-ovulation methods) and withdrawal are not acceptable methods 
of contraception. 
4. Has a stable health status as assessed by the investigator, as
established by physical examination, vital sign measurements, and
medical history.
5. Has access to a consistent and reliable means of telephone contact,
which may be in the home, workplace, or by personal mobile
electronic device.
6. Is able to understand and comply with planned study procedures.
7. Lives a reasonable distance from the clinical site to be able to travel
to and from the clinical site for follow-up visits and agrees to go to
the clinical site for evaluation (or provide medical record access if
evaluated elsewhere) in the event of an AE.
8.Agrees to stay in contact with the clinical site for the duration of the
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendment 5 
Confidential Page 19 study, has no current plans to move from the study area, and 
provides updated contact information as necessary. 
Exclusion Criteria 
Subjects meeting any of the following criteria will be excluded from the 
study: 
1. History of being vaccinated in the past 5 years against pertussis
(subject recall).
2. Any significant past reaction to any component of Boostrix (at the
discretion of the investigator).
3. Subject reported diagnosis of pertussis in the past 10 years (must be
laboratory confirmed or physician diagnosed from medical records).
4. Vital signs by FDA toxicity scoring >1 (may be repeated once
during the screening period to allow for inclusion and the most
recent measurement taken at baseline).
5. Chronic illness being treated actively and with evidence of recent
intervention for worsening or fluctuating symptoms (at the
discretion of the investigator).
6. The subject has a history of active cancer (malignancy) in the last
10 years (exception is subjects with adequately treated
non-melanomatous skin carcinoma, who may participate in the
study).
7. Current use of any smoking products and unwillingness to refrain
from the use of any smoking products from screening through
28 days after the boosting vaccination.
8. Use of narcotic drugs, evidenced by urine toxicology screen or a
history of drug/alcohol abuse within the past 2 years.
9. Has donated blood or suffered from blood loss of more than 450 mL
(1 unit of blood) within 60 days prior to screening or donated
plasma within 14 days prior to screening.
10. Receipt of immunoglobulin, blood-derived products, systemic
corticosteroids, or other immunosuppressant drugs within 90 days
prior to Day 1.
11. Asthma*, obstructive nasal canal, recurrent or acute sinusitis or
other chronic respiratory problems inclusive of the diagnosis of any
significant pulmonary disease. *Asthma as diagnosed with
spirometry showing reversibility of disease and must meet at least
Step 1 classification with current prescription/use of medications to
control symptoms (EPR-3 2007).
12. History of nasal surgery or Bell’s palsy.
13.Use of repeated nasal sprays, Neti pot, routine nasal washing within
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendment 5 
Confidential Page 20 the past 1 month (more than 2 times per week). Subjects must agree 
to refrain from use of any of these modalities through Day 113.  
14. A temporary exclusion to vaccinate if acute respiratory tract
infection or rhinorrhea or temperature >100.4°F (no symptoms for
3 days prior to vaccination day). Subjects may be vaccinated if they
stay within the vaccination window (screening [30 days] or at the
time of the booster [10 days]).
NOTE: If a subject exceeds the screening window, they must be 
reconsented and screening must be reinitiated. 
15. Use of corticosteroids in the respiratory tract (eg, nasal steroids,
inhaled steroids) within 30 days prior to Day 1.
16. Receipt of a licensed vaccine within the last 30 days prior to Day 1
or planned vaccination during the active study conduct through
Day 113. In the case of seasonal influenza, vaccination should not
be withheld and is not contraindicated for subject participation.
However, vaccination should be planned outside of a 30-day pre- 
and 30-day post-vaccination window whenever possible.
17. Known hypersensitivity to any component of the study vaccines.
18. Participation in any other clinical trial for the testing of an
unlicensed product during the previous 6 months or planned during
the study conduct.
NOTE: “Testing” is intended to mean receipt an investigational product. 
Subjects in long term safety follow-up studies where vaccination has 
been completed greater than 6 months prior to this study enrollment are 
allowed. 
19. Inability to adhere to the protocol, including plans to move from the
area.
20. Personal history or family (first degree) history of congenital or
hereditary immunodeficiency.
21. Past or present infection with human immunodeficiency virus,
hepatitis B, or hepatitis C by screening test.
22. Any autoimmune or immunodeficiency disease/condition (inherited
or iatrogenic).
NOTE: Stable endocrine disorders that have a confirmed autoimmune 
etiology (eg, thyroid, pancreatic) are allowed. 
23. Any neurological disease or history of significant neurological
disorder (eg, meningitis, seizures, multiple sclerosis, vasculitis,
migraines*, Guillain-Barré syndrome [genetic/congenital or
acquired]). *Significant neurological migraine includes frequent
migraine (2 times a month or greater), migraine with aura or
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendment 5 
Confidential Page 21 migraine with complications (status migraninosus, persist aura 
without infarction, infarction or aura triggered seizure defined by 
International Classification of Headache Disorders-3 
[ICHD-3 2018). 
24. Any medical condition that, in the opinion of the investigator, might
interfere with the evaluation of the study objectives or might affect
the safety of the individual, (eg, major depression or history of
suicidal attempt).
25. Toxicity grading >1 for screening laboratory test results for specific
kidney, hepatic, and hematologic values for all subjects and in
screening laboratory values for the safety cohort as indicated in
Table 13-2 (may be repeated once during the screening period to
allow for inclusion and the most recent measurement taken at
baseline). See Table 13-2 for specifically designated parameters.
26. Body mass index <17 kg/m2 or >40 kg/m2.
27. Frequent contact with children less than 1 year of age (parent,
childcare worker, nurse, etc.) or residence in the same household as
persons with known immunodeficiency including persons on
immunosuppressant therapy.
28. Study team member or first-degree relative of study team member.
Study Design: This is a multi-center, randomized, placebo-controlled, and 
observer-blinded trial with a 6-month safety follow-up after the last 
vaccination. After signing the informed consent form, subjects will be 
enrolled in the trial and screened over a window of 30 days; screening 
will include obtaining a nasal sample for mucosal pertussis immune 
status. Subjects will also be asked to provide a signed informed consent 
for the use of samples for further pertussis-specific testing or assay 
development. On Day 1, eligible subjects will be randomized to 1 of 
4 treatment arms and receive BPZE1 intranasal vaccine or formulation 
buffer for injection (placebo) (via the VaxINator™ atomization device) 
and a licensed aP comparator vaccine (ie, Boostrix) or sterile normal 
saline (placebo), given by IM injection. To maintain the blind 
throughout the trial period, placebo vaccination via intranasal and IM 
routes, using formulation buffer and normal saline, respectively will be 
included, and unblinded pharmacy staff will manage vaccine logistics, 
preparation, and (if needed) administration but will not be involved in 
study-related assessments or have subject contact for data collection 
after study vaccine administration. Approximately 300 subjects will be 
randomly assigned 2:1 for the first (prime) vaccination with 200 subjects 
assigned to BPZE1 vaccination and 100 subjects assigned to Boostrix 
(aP vaccine) vaccination. During the second (boosting) vaccination, half 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendment 5 
Confidential Page 22 of each of the treatment groups will be further randomly assigned to 
receive BPZE1 or placebo resulting in a 2:2:1:1 randomization scheme. 
Dosing Scheme 
Timing Day 1 Day 85 
Treatment 
Arm Nasal Vaccination IM Vaccination Nasal Vaccination 
BPZE1 Placeboa Boostrix Placebob BPZE1 Placeboa 
A (N  = 100) X - - X X - 
B (N = 100) X - - X - X 
C (N = 50)  - X X - X - 
D (N = 50)  - X X - - X 
Abbreviation: IM, intramuscular. 
a  Intranasal application of 2 × 0.4 mL (0.4 mL per nostril) placebo (formulation buffer). 
b  IM injection of 0.5 mL placebo (normal saline) to the deltoid region. 
As part of the screening procedures, all subjects will provide a nasal 
sample for determination of mucosal (S-IgA) pertussis antibody status, 
with this sample collected at least 6 days prior to randomization. Day 1 
vaccination (primary) will be delivered by intranasal application 
(BPZE1 or placebo) and by IM injection into the deltoid (Boostrix [aP 
vaccine] or placebo), with subjects randomized to receive 1 of the 
4 final treatment regimens. Nasal secretion sampling for mucosal 
antibody response (S-IgA ELISA) to pertussis-specific antigens will 
occur at baseline (screening) and Days 29 and 78 post-primary 
vaccination. Serum sampling for antibody response (IgG and IgA 
ELISA) will occur at baseline (Day 1, prior to primary vaccination) and 
on Days 29 and 85 (prior to boosting vaccination). Subjects will be 
tested for BPZE1 clearance (colonization) from the nasal tract via a 
standard nasal secretion sampling on Day 78. There needs to be at least 
6 days between the nasal secretion sampling, which will occur at Visit 4 
(Day 78), and the boosting intranasal vaccination. The boosting 
vaccination visit (Day 85 [+7 days]) will consist of all subjects receiving 
intranasal administration (BPZE1 or placebo) with half of the subjects 
who received BPZE1 for the primary vaccination receiving a second 
dose of BPZE1 and the other half of subjects receiving placebo 
(formulation buffer for injection). Similarly, half of the subjects 
receiving Boostrix will receive BPZE1 and half will receive placebo. 
Colonization following the boosting vaccination will be measured on 
Days 92, 96, and 113 by standard nasal secretion sampling. Any subject 
who tested positive by pertussis culture Day 113 will be retested at Day 
254 or at the time of the end-of-study visit. Chronic carriage of BPZE1  
has not been reported (ie, the majority of subjects have been clear at 
Day 29 and no subject has had positive cultures at Day 46) and is 
therefore not expected. Any subject who remains positive for pertussis at 
Day 254 will be provided a short course of azithromycin, which is 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 23 clinically used to eradicate B. pertussis  from the nasopharynx. Should a 
subject be allergic to azithromycin, an appropriate  antibiotic will be 
substituted that has effectiveness against B. pertussis . Mucosal (S-IgA 
ELISA) and serum response (IgG and IgA ELISA) to pe rtussis-specific 
antigens after boosting will be tested on Days 113,  169, and 254. 
The first 48 subjects randomly assigned will be des ignated the safety 
lead-in cohort and will be sequentially enrolled by  escalating dose. The 
first 24 subjects will be randomly assigned as note d above in a ratio of 
2:1 to receive active products of either an intrana sal dose of 10 7 CFU of 
BPZE1 or IM Boostrix. These subjects will be follow ed through Day 8 
with safety laboratory tests, reactogenicity, and A E assessments with 
daily review by the medical monitor for activation of any halting rule. 
Following accumulation of all safety data through D ay 8 
post-vaccination and without a safety pause being t riggered, the 
24 additional subjects will be randomly assigned 2: 1 to receive active 
products of either an intranasal dose of 10 9 CFU of BPZE1 or IM 
Boostrix. To maintain the blind for intranasal and IM administered 
products, all subjects will also receive appropriat e placebo vaccinations. 
All safety lead-in subjects will have safety labora tory testing at baseline 
(screening), and on Days 8, 85 (prior to vaccinatio n), and 92. Subjects 
will continue with the booster using the same intra nasal dose level 
(10 7 CFU or 10 9 CFU) assigned for the first dose. The medical moni tor 
has the authority to request a review by the Safety  Monitoring 
Committee should a halting rule be initiated or the re are any other safety 
concerns. The Safety Monitoring Committee will conv ene after the 
subjects in the entire safety lead-in cohort (both dose levels) have 
completed Day 8 (Visit 2) and will review all safet y data through Day 8 
(reactogenicity and safety laboratory results) and any AEs which have 
occurred since study initiation. The Safety Monitor ing Committee will 
be authorized to allow the remainder of the subject s to be randomly 
assigned. The randomization scheme for the safety l ead-in will follow 
the same scheme as the full cohort for second vacci nation such that half 
the BPZE1 and half the Boostrix vaccinated subjects  will receive 
intranasal BPZE1 vaccination on Day 85 and the othe r half will receive 
placebo. 
 
 
 
 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 24 Table 1 Dosing and Safety Lead-In Cohort 
BPZE 
1 Dose BPZE1 Boostrix Trigger to 
advance Review 
Process Advancing 
to 
10 7 N = 16 N = 8 Day 8 safety on 
10 7 dosing 
cohort Pause rules; 
daily medical 
monitor 
reviews  10 9 safety 
lead-in 
10 9 N = 16 N = 8 Day 8 safety on 
full safety lead-
in cohort; all 
adverse events  Safety 
Monitoring 
Committee 
review  Full cohort 
All subjects will be monitored for 60 minutes after  vaccine 
administration on Days 1 and 85. After the subjects  have been monitored 
for 60 minutes post-vaccination, vital signs will b e collected and a 
post-vaccination examination for reactogenicity (lo cal, nasal/respiratory, 
and systemic) with toxicity grade will be completed . 
Subjects will receive a daily subject diary on Days  1 and 85 after each 
vaccination. All subjects will record reactogenicit y in the daily subject 
diary starting the same day of the primary (Day 1) and boosting 
(Day 85) vaccinations and for 7 additional days (no t counting 
vaccination day). For primary vaccination site-spec ific local (arm), 
nasal/respiratory, general systemic reactogenicity reactions, and other 
unsolicited symptoms/complaints (including start an d stop dates) will be 
recorded and standard toxicity grading will be appl ied by the 
investigator at the subsequent visit (Visit 2). For  the boost vaccination, 
nasal/respiratory, general systemic reactogenicity reactions, and other 
unsolicited symptoms/complaints (including start an d stop dates) will be 
recorded and standard toxicity grading will be appl ied by the 
investigator at the subsequent visit (Visit 6). The  clinical staff will 
review the information from the subject diaries wit h the subjects on 
Days 8 and 92 (Visits 2 and 6). Should any reactoge nicity event extend 
beyond 7 days post-vaccination and be clinically si gnificant by toxicity 
grade 1 or greater, then it will be entered as an A E with the same start 
date as the reactogenicity event and followed to re solution. 
All AEs will be monitored through 28 days after the  primary and 
boosting vaccinations. Unsolicited AEs related to v accination will be 
monitored through Day 113 (unless resolved or felt to be stable at an 
earlier date). Serious AEs and AEs of special inter est (if newly 
identified) will be monitored to the end of the stu dy. The primary 
database lock will occur at Day 113, and all data c ollected through 
Day 113 will be included in the clinical study repo rt and submitted to 
regulatory authorities. A subsequent longer-term sa fety follow-up, 
including long er term persistence of immune responses, will occur  
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 25 through Day 254. These data will be provided, follo wing a second 
database lock, in an addendum to the clinical study  report. Subjects will 
return to the clinical site on Day 254 (±15 days) f or end-of-study 
procedures. 
A subset of no more than 60 subjects (randomly assi gned to the 10 9 CFU 
dose) will opt in to provide blood samples for peri pheral blood 
mononuclear cell harvesting on Days 1, 8, and 92. 
Estimated 
Study Duration: Study duration is approximately 15 months; subject participation 
duration is approximately 10 months. 
Immunogenicity 
Assessments: Immune measurements (ELISA) will be conducted on se rum (IgG and 
IgA) and nasal secretion (S-IgA) for the common per tussis antigens of 
PT, FHA, PRN, FIM 2/3 and on serum (IgG) and nasal secretions 
(S-IgA) for BPZE1 whole cell extract. Testing of ad ditional antigens 
specific to B. pertussis  may be performed at a later date as BPZE1 
induces broader immunity more similar to whole cell  pertussis and does 
not contain the purified antigen levels of PT, FHA,  and PRN found in 
Boostrix. Subjects will be asked to provide a signe d informed consent 
for the use of samples for further pertussis-specif ic testing or assay 
development. Aliquots of collected samples from thi s study may be 
retained for additional testing of antigens specifi c to B. pertussis  for a 
maximum of 10 years (starting from the date at whic h the last subject 
had the last study visit), unless local rules, regu lations, or guidelines 
require different timeframes or different procedure s, in accord with 
subject consent. Testing for colonization using B. pertussis  culture 
following the primary vaccination and post-boost wi ll also occur. 
Colony counts as well as culture positivity (yes/no ) will be included in 
the colonization assessments post-boosting.  
Safety 
Assessments: Safety assessments will include the following: 
 Vital sign measurements (oral temperature, pulse ra te, and blood 
pressure) 
 Physical examination 
 Clinical safety laboratory tests (hematology, chemi stry, coagulation 
at baseline and in the safety lead-in cohort follow ing vaccination) 
and urine pregnancy test in women of childbearing p otential 
 Solicited local, nasal/respiratory, and systemic re actogenicity 
symptoms during the 7 days after each vaccination ( Days 1 
through 8 and 85 through 92). Local reactogenicity will only be 
monitored following the IM vaccination. 
 Adverse events through 28 days after the primary an d boosting 
vaccination 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 26  Adverse events associated with vaccination through Day 113 (unless 
resolved or stable at an earlier date) 
 Serious AEs and any AEs of special interest from th e time of the 
primary vaccination through the last visit 
Study Drug, 
Dosage, and 
Route of 
Administration: Live attenuated B. pertussis  BPZE1 vaccine, 2 × 0.4 mL (0.4 mL per 
nostril containing half the dose 5 × 10 8 bacteria to give a total dose of 
10 9 CFU) and a dilution of the same stock to achieve 1 0 7 CFU in the 
same total volume for the first cohort lead-in (n =  24 subjects). See the 
pharmacy manual for specific dilution requirements.  
Boostrix IM injection, 0.5 mL to the deltoid region  (aP vaccine, 
manufactured by GlaxoSmithKline) 
Placebo (BPZE1 formulation buffer for injection) 2 × 0.4 mL (0.4 mL 
per nostril)  
Placebo IM injections of 0.5 mL sterile normal sali ne to the deltoid 
region 
Sample Size: The sample size is based on clinical considerations  but not a statistical 
power analysis as the study does not test any forma l null hypothesis. A 
total of 300 subjects will be globally assigned at 2:2:1:1 allocation ratio 
and receive BPZE1 intranasal administration with pl acebo IM or 
Boostrix IM with placebo intranasal administration on Day 1 and then 
BPZE1 or placebo intranasal administration on Day 8 5. 
Statistical 
Methods: The objectives of this study are to assess the nasa l mucosal and systemic 
immunogenicity, reactogenicity, and general safety parameters of 
lyophilized BPZE1 at 10 7 and 10 9 CFU administered intranasally via 
VaxINator atomization device to either a single (pr ime) or 2 dose (prime 
+ boost) schedule. Secondly, to compare responses t o a licensed aP 
comparator vaccine (ie, Boostrix) given by IM injec tion, in healthy 
volunteers 18 to 50 years of age, as well as to ass ess safety and immune 
response to BPZE1 boost after Boostrix priming. 
Statistical analysis will be performed using SAS so ftware Version 9.3 or 
later. Continuous variables will be summarized usin g the mean, 2-sided 
95% CI of the mean, SD, median, minimum value, and maximum value. 
Categorical variables will be summarized using freq uency counts and 
percentages, as well as 2-sided 95% CI for proporti ons computed using 
Clopper-Pearson method. Where applicable, data anal yses will be 
conducted for the prime period (prior to boosting) and boost period (at 
or after boosting). 
Version and 
Date of 
Protocol: Version 6.0; 20 November 2019 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 27 List of Abbreviations 
Abbreviation Definition 
AE adverse event 
aP acellular pertussis 
CDROM compact disc read-only memory 
CFR Code of Federal Regulations 
CFU colony-forming units 
CRO contract research organization 
CSR clinical study report 
DNT dermonecrotic toxin 
eCRF electronic case report form 
ELISA enzyme-linked immunosorbent assay 
FDA US Food and Drug Administration 
FHA filamentous hemagglutinin 
FIM fimbriae 
GCP Good Clinical Practice 
GMFR Geometric Mean Fold Rise 
GMT Geometric Mean Titer 
ICF informed consent form 
ICH International Council for Harmonisation 
IgA immunoglobulin A 
IgG immunoglobulin G 
IM intramuscular 
IRB institutional review board 
MedDRA Medical Dictionary for Regulatory Activities  
PBMC peripheral blood mononuclear cell 
PRN pertactin 
PT pertussis toxin 
S-IgA secretory immunoglobulin A 
SAE serious adverse event 
SMC Safety Monitoring Committee 
SUSAR suspected unexpected serious adverse reaction  
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 28 Abbreviation Definition 
TCT tracheal cytotoxin 
WFI water for injection 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 29 1 Introduction 
1.1  Background Information 
Currently registered acellular pertussis (aP) vacci nes protect against respiratory disease but 
not against colonizing Bordetella pertussis  infection and transmission. B. pertussis  is a 
gram-negative bacterium and a causative agent of pe rtussis, more commonly known as 
whooping cough. In a nonhuman primate model, conval escence from a natural B. pertussis  
infection protected against colonizing infection an d transmission caused by a subsequent 
virulent B. pertussis  challenge (Warfel et al 2014), ie, a natural infec tion confers sterilizing 
immunity. Similarly, a single intranasal administra tion of the highly attenuated live B. 
pertussis  vaccine BPZE1 has demonstrated in the nonhuman pri mate model the ability to 
reduce the bacterial burden of a substantial B. pertussis  challenge by more than 99.8% 
compared to prior studies challenging baboons immun ized with 3 doses of aP vaccine (Locht 
et al 2017). ILiAD has licensed BPZE1 from the Inst itut Pasteur de Lille and Inserm with 
worldwide rights and the company is conducting furt her clinical and regulatory development.  
Despite the dramatic decline in whooping cough case s and deaths in industrialized nations 
during the 20th century due to public health vaccin e initiatives, recent decades have 
witnessed a sharp increase in cases and it is gener ally agreed that there is a critical need for a 
new and more effective vaccine targeting B. pertussis . In 2014, it was estimated there were 
24.1 million pertussis cases and 160,700 deaths fro m pertussis in children younger than 
5 years of age, with 53% of the estimated deaths be ing in infants younger than 1 year 
(Yeung et al 2017). Infants are not fully protected  and require a series of vaccinations against 
pertussis. With the current acellular vaccines bein g ineffective against colonization (and 
therefore transmission) there is little to any herd  immunity that can develop, leaving infants 
at risk for acquiring pertussis from close contacts . As a potential solution to this problem, the 
BPZE1 vaccine has been developed to be given as a s ingle intranasal administration. Unlike 
existing vaccines, BPZE1 has the potential to preve nt transmission of B. pertussis  from 
siblings and adults to neonatal infants. While ulti mately intended for vaccinating neonatal 
infants, a nearer term solution is to immunize adul ts and adolescents with BPZE1 to prevent 
transmission of B. pertussis  to vulnerable infants. 
BPZE1 was engineered by genetically altering or rem oving 3 B. pertussis  toxins: pertussis 
toxin (PT), tracheal cytotoxin (TCT), and dermonecr otic toxin (DNT). Genetic stability of 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 30 liquid BPZE1 formulation was demonstrated in vitro and in vivo. The safety of liquid BPZE1 
has been assessed in immunocompetent and immunosupp ressed animals (Feunou et al 2008; 
Meilcarek et al 2006; Meilcarek et al 2010; Skerry et al 2009). These results contributed to 
downgrading BPZE1 from a biosafety level 2 organism  to biosafety level 1 in France and 
other European countries. Good Laboratory Practice- compliant toxicological studies have 
confirmed the safety of BPZE1 in 2 animal models (m ouse and rabbit) (ILiAD 
Biotechnologies 2017).  
BPZE1 in a liquid formulation has been studied at v arious doses from 10 3 colony-forming 
units (CFU) to 10 9 CFU in 2 Phase 1 clinical studies in Sweden with n o vaccine-related 
serious adverse events (SAEs) and comparable genera l adverse events (AE) to placebo 
controls. A total of 78 healthy subjects have now r eceived intranasally administered BPZE1 
in a liquid formulation. The most recent Phase 1b s tudy has demonstrated the ability for a 
0.4 mL (400 µL) per nostril dose of 10 7, 10 8, and 10 9 CFU BPZE1 to achieve transient 
nasopharyngeal colonization in >80% of subjects. Fu rthermore, 92% of the subjects in the 
10 7 and 10 8 CFU/dose groups and 100% of the 10 9 CFU group had a positive serological 
response (immunoglobulin G [IgG] or immunoglobulin A [IgA]) to any of the 4 B. pertussis  
antigens tested, and 100% of the 10 9 CFU subjects had a positive serological response ( IgG 
or IgA) to 2 or more of the antigens tested. The 109 CFU dosage appears to be the most 
promising to elicit the needed immune response in t he majority of adults. None of the 
placebo subjects had a positive serological respons e (IgG or IgA) to 2 or more antigens tested 
(ILiAD Biotechnologies 2017). 
A separately ongoing Phase 2a clinical study is com paring 2 doses (10 7 and 10 9 CFU) of the 
lyophilized formulation of BPZE1, delivered by the VaxINator™ conical-shape atomization 
device connected to a 1-mL syringe. The study will assess the new lyophilized formulation of 
the BPZE1 vaccine to be evaluated in US adults and will provide an opportunity to 
characterize the immunological response of 2 differ ent dosages delivered by nasal 
immunization. The main advantage of the lyophilized  BPZE1 formulation is long-term 
stability and storage at refrigeration temperature instead of storage at a very low freezing 
temperature. Mouse potency and adherence assays hav e demonstrated similar results for the 
lyophilized and liquid formulations. Prior to vacci nation, the lyophilized product will be 
reconstituted, and vaccine will be delivered as a l iquid formulation using a nasal applicator to 
improve consistent delivery.  
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 31 For this Phase 2b study, the BPZE1 experimental vac cine will be supplied in a lyophilized 
vial for reconstitution prior to intranasal adminis tration via the VaxINator atomization device. 
Two lyophilized BPZE1 experimental vaccine doses, 1 0 7 CFU and 10 9 CFU, will be 
evaluated in the safety lead-in cohort of the 2b st udy with subjects continuing with the same 
intranasal dose level through the booster (10 7 CFU or 10 9 CFU). The dose targeted for the 
remainder of the subjects in the Phase 2b study wil l be 10 9 CFU unless a safety concern 
arises and the Safety Monitoring Committee (SMC) re commends proceeding with the 10 7 
CFU dose only. The 10 9 CFU is described throughout this protocol as the d efault dose level 
for the full cohort for purposes of consistent pres entation. 
The vaccine will be shipped from ILiAD’s European c ontract manufacturing organization to 
the contract research organization’s (CRO’s) reposi tory and distribution center and should be 
stored at –20°C or below prior to shipping to the c linical sites, where the vaccine can be 
stored at –10°C or below, and is expected to have a  1-year shelf-life that can be extended 
with periodic ongoing retests conducted every 4 mon ths by ILiAD’s European contract 
manufacturing organization. The lyophilized BPZE1 i s reconstituted in 1 mL of sterile water 
for injection (WFI), with 0.8 mL per dose removed f rom the vial for use. The reconstituted 
vaccine is recommended to remain at room temperatur e for 60 minutes or less prior to 
vaccination and therefore attention to the timing o f pharmacy reconstitution and vaccination 
of individuals will be critical. After correct dilu tion (to obtain 10 7 or 10 9 CFU per the 
pharmacy manual) the VaxINator will be attached to the syringe filled with reconstituted 
BPZE1, with half of the dose (0.4 mL) administered into each nostril. For the placebo control 
nasal vaccination, the formulation buffer used for BPZE will be similarly diluted with sterile 
water (WFI) and used with the vaccinator at the sam e dose (0.4 mL per nostril). Only clinical 
staff trained on use of the VaxINator will be allow ed to provide intranasal vaccinations and 
the study blind will be maintained by use of an opa que syringe (or other similar blinding 
technique). Unblinded study drug personnel will del iver the intramuscular (IM) vaccination 
unless the syringes can be masked to ensure no unbl inding will occur for clinical staff 
involved in subject assessments.  
1.2  Rationale 
The availability of a cost-effective pertussis vacc ine that provides improved efficacy and 
prolonged protection with the potential to reduce o r eliminate transmission would present a 
breakthrough in the prevention of colonizing pertus sis infections. This novel approach may 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 32 not only protect BPZE1-vaccinated individuals from B. pertussis  infection but may also 
reduce the B. pertussis  reservoir in the adult population. The ability to prevent colonization 
by wild type B. pertussis  that enable transmission may facilitate substantia l reduction in the 
incidence of pertussis in infants. 
The intranasally administered BPZE1 vaccine provide s an opportunity to generate a locally 
effective nasal mucosal antibody response at the si te of potential exposure, and thereby 
mimics the route of entry of the wild type pathogen  and results in a broader immune response 
(type 1 T helper cells, type 2 T helper cells, and nasal mucosal immune responses) (Wearing 
and Rohani 2009). The study population, healthy adu lts, has been chosen to maximize the 
quality of immunogenicity data while minimizing ris k and potential safety signals.  
We hypothesize that the BPZE1 vaccine will be safe and induce nasal mucosal immunity 
beyond that observed with standard vaccination with  Boostrix ™ and that BPZE1 will also 
induce systemic immunity. Immunity will be measured  in enzyme-linked immunosorbent 
assays (ELISA) specific for PT, filamentous hemaggl utinin (FHA), pertactin (PRN), and 
fimbriae (FIM) 2/3, and a broader pertussis ELISA d eveloped with BPZE1 whole cell 
extract. In addition, we hypothesize that a priming  dose of intranasal BPZE1 vaccine will 
result in fewer subjects colonized (eg, lower colon y counts) following a boosting dose of 
BPZE1, whereas a priming dose of Boostrix will not reduce colonization following a 
boosting dose of BPZE1, ie, Boostrix will generate less nasal mucosal immunity to prevent 
colonization by the BPZE1 live attenuated B. pertussis  strain. Lastly, given that the majority 
of the population has received pertussis vaccinatio n on multiple occasions, this study will 
assess the safety and immune response of BPZE1 as b ooster delivered after a prime dose of 
Boostrix in an adult population. 
1.3  Potential Risks and Benefits 
1.3.1  Potential Risks 
Potential risks include risks of study participatio n (in general), specific risks to study 
subjects, and theoretic risks to the environment th rough the introduction of an attenuated 
B. pertussis strain into human hosts. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 33 1.3.2  Risks of Study Participation 
The risks of study participation include exposure t o the study product, maintenance of 
confidentiality, and side effects of phlebotomy. Al l risks will be minimized to every extent 
possible.  
1.3.3  BPZE1 Risks to Study Subjects 
The risks of BPZE1 administration are expected to b e minimal and clinically manageable. 
B. pertussis  colonization is strictly limited to respiratory ep ithelium without dissemination of 
the bacteria outside the respiratory tract, which a lso excludes systemic bacteremia of the 
BPZE1 strain.  
B. pertussis  is spread mainly by aerosol formed by coughing of infected persons. The 
coughing is induced by the TCT, which is more than 95% reduced in BPZE1. The BPZE1 
strain is not expected to induce coughing, therefor e transmission is highly unlikely. 
Bordetella  species have fastidious growth requirements and ha ve limited survival time 
outside the human body.  
B. pertussis  has not been shown to be allergenic in any preclin ical or clinical studies to date, 
nor to have any of the excipients in the lyophilize d formulation. BPZE1 has been shown to 
protect against airway inflammation induced by alle rgens or viral infections in a murine 
model (Althouse and Scarpino 2015). BPZE1 has also been shown to protect against wild 
type B. pertussis  infection 3 hours after immunization in a murine m odel (Mielcarek et al 
2006). However, there remains a theoretical risk of  allergic reaction, as is present with any 
vaccine product. 
BPZE1 vaccine or the placebo will be administered n asally via the VaxINator atomization 
device attached to a syringe to healthy adult volun teers under strictly controlled conditions. 
The VaxINator atomizes the liquid vaccine as it exi ts the syringe. There are no additional 
risks to study subjects based on the use of the Vax INator device.  
To minimize the risk of transmission, the subjects will stay at the study center for at least 
60 minutes after administration on Days 1 and 85. I n addition, subjects with frequent contact 
with children less than 1 year of age (parent, chil dcare worker, nurse, etc.) or subjects who 
live in the same household as individuals with know n immunodeficiency or individuals on 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 34 immunosuppressant therapy will be excluded from par ticipation in the study. The attenuated 
BPZE1 bacteria colonize the upper respiratory tract  similarly to wild-type B. pertussis . 
Colonization of the live organism will be assessed from nasopharyngeal sampling performed 
on Days 78 (after a mucosal pertussis nasal antibod y collection is completed), 92, 96, and 
113 (after a mucosal pertussis nasal antibody colle ction is completed). Any subject who 
tested positive by pertussis culture at Day 113 wil l also have a nasal collection taken for 
pertussis culture on Day 254. Any subject who remai ns positive at Day 254 will be provided 
a short course of azithromycin, which is clinically  used to eradicate B. pertussis  from the 
nasopharynx. Should a subject be allergic to azithr omycin, an appropriate antibiotic will be 
substituted that has effectiveness against B. pertussis . 
Furthermore, in animal studies, when female mice we re vaccinated with BPZE1 shortly 
before mating, no negative effect on either the pre gnancy or their offspring was observed. 
The offspring were protected against B. pertussis  challenge (Feunou et al 2016).  
Previous clinical trials completed in subjects who received 10 7, 10 8, or 10 9 CFU/subject 
reported AEs. None of the subjects had spasmodic co ugh of grade 2 or more or any other AE 
related or possibly related to vaccination of grade  3 or higher. Among 54 subjects 
(42 vaccinated with an active vaccine and 12 with p lacebo), the most frequently solicited 
AEs during the first 28 days were sneezing (n = 61 in 29 subjects), fatigue (n = 51 in 
28 subjects), headache (n = 42 in 27 subjects), rhi norrhea (n = 41 in 26 subjects), and nasal 
congestion (n = 39 in 25 subjects). The reported sy mptoms were mostly mild or moderate. 
There were no consistent signals for differences in  AE occurrence between placebo and the 
different dose groups. 
In summary, the risk assessment for this study show s a very low potential risk for the study 
subjects and impact associated with administering B PZE1.  
1.3.4  Risks to the Environment or Potential for Interacti on With 
Wild-Type B. Pertussis  Strains 
To avoid accidental exposure actions should be take n to minimize generation of aerosols, 
since the bacterium is strictly a respiratory tract  organism. The subjects and clinical staff 
members should wear eye-protective glasses and mask s during the vaccination. Persons 
handling the BPZE1 bacteria should wear gloves and must wash their hands with a suitable 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 35 disinfecting soap before touching their skin and ey es. Effective antibiotic treatment with 
azithromycin (or an appropriate antibiotic if the s ubject is allergic to azithromycin) should be 
given in case of accidental transmission to other h umans. 
The attenuated strain of B. pertussis  (BPZE1) was engineered by genetically altering or 
removing 3 B. pertussis  toxins: PT, TCT, and DNT. The genetic modification s (replacement 
of the ampG  gene, deletion of the DNT, and the mutations of th e PT) are not expected to alter 
the host range of B. pertussis BPZE1 compared to the wild-type B. pertussis .  
Due to the robust preclinical safety data, BPZE1 ha s been classified as a Biosafety 
Level 1 organism by French authorities Republique Francaise Ministere De L’enseignement 
Superieur Et De La Recherche (French Ministry of Hi gher Education and Research) . 
Germany, Belgium, Spain, and Sweden  have accepted the French Authority’s Biosafety 
Level 1 rating for the purpose of manufacturing and  clinical studies.  
The genetic modifications in BPZE1 strongly increas e the in vivo and in vitro safety: 
 The double nucleotide mutation in the substrate bin ding and the active site of the PT 
results in a strong reduction of the enzyme activit y. 
 The replacement of the B. pertussis ampG  gene by the Escherichia coli ampG  gene 
results in an over 95% reduction in release of the TCT in the medium. 
 The DNT is not expressed in the BPZE1 strain. 
 BPZE1 is not invasive and has no selective advantag e in the environment. The 
potential for exchange of genetic material is virtu ally nonexistent since B. pertussis  
does not harbor plasmids or conjugative transposons . In addition, B. pertussis  
Tohama I (origin of BPZE1) does not harbor intact p rophage genomes and is 
therefore incapable of producing functional phage p articles. 
Chronic carriage of B. pertussis  has not been reported and is therefore not expecte d. No 
cross-contamination between the subjects was observ ed in the previous Phase 1 clinical trials 
of BPZE1, nor was any risk to the family members of  study subjects observed. In case of 
transmission to  other humans, accidentally exposed, an efficient t reatment against 
B. pertussis  is commercially available and is based on administ ering erythromycin. BPZE1 
has been shown to be sensitive to erythromycin. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 36 In summary, the preliminary risk assessment for thi s study suggests there is an extremely low 
risk for potential environmental impact associated with administering the BPZE1 to study 
subjects. 
1.3.5  Boostrix Risks to Study Subjects 
The risks of Boostrix administration are expected t o be minimal and clinically manageable. 
Local adverse reactions include pain, redness, swel ling, and injected arm circumference 
increase. General adverse reactions include headach e, fatigue, gastrointestinal symptoms, and 
fever. 
The tip caps of the prefilled syringes contain natu ral rubber latex which may cause allergic 
reactions.  
If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing 
tetanus toxoid, the risk of Guillain-Barré syndrome  may be increased following a subsequent 
dose of tetanus toxoid-containing vaccine, includin g Boostrix.  
Syncope can occur in association with administratio n of injectable vaccines, including 
Boostrix. Syncope can be accompanied by transient n eurological signs such as visual 
disturbance, paresthesia, and tonic-clonic limb mov ements. Procedures for administration 
should be in place to avoid falling injury and to r estore cerebral perfusion following syncope.  
Progressive or unstable neurologic conditions (eg, cerebrovascular events and acute 
encephalopathic conditions) are reasons to defer va ccination with a pertussis-containing vaccine, 
including Boostrix. It is not known whether adminis tration of Boostrix to subjects with an 
unstable or progressive neurologic disorder might h asten manifestations of the disorder or affect 
the prognosis. Administration of Boostrix to subjec ts with an unstable or progressive neurologic 
disorder may result in diagnostic confusion between  manifestations of the underlying illness and 
possible adverse effects of vaccination.  
Persons who experienced an Arthus-type hypersensiti vity reaction following a prior dose of a 
tetanus toxoid-containing vaccine usually have a hi gh serum tetanus antitoxin level and should 
not receive Boostrix or other tetanus toxoid-contai ning vaccines unless at least 10 years have 
elapsed since the last dose of tetanus toxoid-conta ining vaccine.  
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 37 As with any vaccine, if administered to immunosuppr essed individuals, including individuals 
receiving immunosuppressive therapy, the expected i mmune response may not be obtained.  
Prior to administration, the healthcare provider sh ould review the immunization history for 
possible vaccine sensitivity and previous vaccinati on-related adverse reactions to allow an 
assessment of benefits and risks. Epinephrine and o ther appropriate agents used for the control of 
immediate allergic reactions must be immediately av ailable should an acute anaphylactic reaction 
occur.  
1.3.6  Known Potential Benefits 
The benefits of the study lie primarily in the oppo rtunities to science and humanity. No direct 
personal benefit from participation in the study ca n be guaranteed, as the vaccine may or may 
not confer protection in humans.  
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 38 2 Study Objectives and Endpoints 
2.1  Primary Objectives 
2.1.1  Primary Immunogenicity Objective 
 To assess nasal mucosal secretion immune response ( secretory Ig A [S-IgA]) 
following intranasal vaccination with BPZE1 (10 9 CFU) when used as a single (eg, 
prime) or 2-dose (eg, prime + boost) series. 
2.1.2  Primary Safety Objective 
 To assess reactogenicity (all) and specific safety laboratory parameters (safety lead-in 
cohort only) following intranasal vaccination with BPZE1 either 10 7 CFU (safety 
lead-in cohort only) or 10 9 CFU (safety lead-in cohort and full cohort), in he althy 
adults. 
2.2  Secondary Objectives 
2.2.1  Secondary Immunogenicity Objectives 
 To assess the systemic immune response (IgG, IgA) f ollowing intranasal vaccination 
with BPZE1 when used as a single (eg, prime) or 2-d ose (eg, prime + boost) series. 
 To assess nasal mucosal secretion (S-IgA) and syste mic (IgG, IgA) immune response 
following intranasal vaccination with BPZE1 boost d ose proceeded by Boostrix or 
BPZE1 prime dose. 
 To assess nasal mucosal secretion (S-IgA) and syste mic (IgG, IgA) immune response 
through 9 months after a single (eg, prime) dose an d 6 months after a 2-dose series 
(eg, prime + boost), where the prime dose is BPZE1 or Boostrix, and BPZE1 (or 
placebo) is the boost dose. 
 To assess nasal mucosal secretion (S-IgA) and syste mic (IgG, IgA) immune response 
following immunization with BPZE1 or Boostrix prime  dose, with or without a 
BPZE1 boost dose, in relation to baseline immunity status (positive [Yes/No]) of 
pertussis antibodies PT, PRN, FHA, and FIM 2/3. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 39 2.2.2  Secondary Colonization Objectives 
 To assess nasopharyngeal colonization or clearance of BPZE1 in either a prime or 
prime + boost strategy, and in relationship to vacc ination strategies with Boostrix. 
2.2.3  Secondary Safety Objectives 
 To describe (severity and clinical significance) of  vaccine-related AEs following a 
single or 2-series intranasal vaccination (prime or  prime + boost) with BPZE1 or 
Boostrix prime dose with or without a BPZE1 boost d ose. 
 To describe all SAEs during the study. 
2.3  Exploratory Objective 
 To examine cell-mediated (eg, B cell, CD4 T lymphoc ytes + T cell, CD8 
T lymphocytes + T cell) responses in a subset of no  more than 60 subjects using 
peripheral blood mononuclear cells (PBMCs) to be co llected at baseline and 8 days 
post-vaccination (prime and boost). This subset wil l be from the randomized cohort 
population of 10 9 CFU BPZE1 only. 
 To further characterize nasal mucosal secretion and  serum immunological responses 
across time, relative to baseline status and relati ve to vaccination response, with the 
current assays and with any future assays developed  for BPZE1.  
2.4  Primary Endpoints 
2.4.1  Primary Immunogenicity Endpoints 
The primary immunogenicity endpoints of this study are: 
 Mucosal seroconversion (nasal mucosal secretion sam pling):  Proportion of 
subjects who achieve seroconversion against at leas t 1 pertussis antigen (PT, FHA, 
PRN, FIM 2/3, or BPZE1 whole cell extract) in nasal  secretions on Day 29 or 113 
(prime or prime + boost). 
Mucosal seroconversion is defined as a 2-fold incre ase over the baseline value 
(collected during screening) or a 4-fold increase o ver the minimal limit of assay 
detection (whenever the baseline value falls below the limits of assay detection) for 
any of the pertussis-specific antibodies (S-IgA ELI SA): PT, FHA, PRN, FIM 2/3, or 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 40 BPZE1 whole cell extract. Seroconversion will be ca lculated based on absolute titer 
response over baseline and by standardizing pertussis-specific ELISA responses  
relative to non-pertussis-specific total nasal muco sal secretion (eg, IgA). To be further 
defined during assay development and within the sta tistical analysis plan. 
Mucosal baseline samples will be taken at the scree ning visit. 
2.4.2  Primary Safety Endpoints 
The primary safety endpoints of this study are: 
 Solicited AEs (local, nasal/respiratory, and system ic reactogenicity events) for 7 days 
following each vaccination by severity score, durat ion, and peak intensity. Local 
reactogenicity will only be monitored following the  IM vaccination. 
 Safety laboratory results (serum chemistry, hematol ogy, coagulation) by US Food and 
Drug Administration (FDA) toxicity score (change fr om baseline or absolute toxicity 
score) in the safety lead-in cohort at Day 8 follow ing each vaccination. In the case of 
no toxicity classification, the score of 0 will be assigned. 
2.5  Secondary Endpoints 
2.5.1  Secondary Systemic Immunogenicity Endpoints 
The secondary systemic immunogenicity (serum sampli ng [expressed separately for IgG, 
IgA, and IgG or IgA ELISA when possible]) endpoints  of this study are: 
 Proportion of subjects who achieve seroconversion a gainst pertussis antigen (PT, FHA, 
PRN, FIM 2/3, or BPZE1 whole cell extract) over bas eline for: 
 At least 1 antigen on each  of the Days 29, 85, 113, 169, or 254 
 At least 1 antigen on any of the Days 29, 85, 113, 169, or 254 
 At least any 1  antigen on all  Days 29, 85, 113, 169, or 254 
Systemic seroconversion is defined as a 2-fold incr ease over the baseline value or a 
4-fold increase over the minimal limit of assay det ection (whenever the baseline value 
falls below the limits of assay detection). Both Ig G and IgA ELISA will measure 
antibodies against the following pertussis-specific  antigens of PT, FHA, PRN, and FIM 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 41 2/3, and IgG ELISA will measure antibodies against broader pertussis-specific antigens 
in BPZE1 whole cell extract. 
Serum baseline samples will be taken at Day 1 prior  to vaccination. 
 Proportion of subjects who achieve seroconversion ( IgG ELISA only) against BPZE1 
whole cell extract over baseline: 
 On either  Day 29 (prime) or 113 (boost) 
 On both  Days 29 (prime) and 113 (boost). 
 Proportion of subjects who achieve seroconversion a gainst the aP antigens PT, FHA, and 
PRN over baseline: 
 On either  Day 29 (prime) or 113 (boost) 
 On both  Days 29 (prime) or 113 (boost). 
 Proportion of subjects who achieve seroconversion a gainst 2 or more pertussis antigens 
(PT, FHA, PRN, FIM 2/3, and BPZE1 whole cell extrac t) over baseline: 
 On each  of the Days 29, 85, 113, 169, or 254 
 On any  of the Days 29, 85, 113, 169, or 254 
 At least the same 2 antigens  on all  Days 29, 85, 113, 169, and 254. 
 Proportion of subjects who demonstrate boosting for  each pertussis antigen (PT, FHA, 
PRN, FIM 2/3, and BPZE1 whole cell extract) on  Day 113. Boost is defined as at least a 
2-fold increase from the pre-boost sample taken on Day 85. 
 The Geometric Mean Fold rise (GMFR) against each pe rtussis antigen (PT, FHA, PRN, 
FIM 2/3, and BPZE1 whole cell extract): 
 On Days 29, 85, 113, 169, and 254 over baseline  (Day 1) 
 On Days 113, 169, and 254 over pre-boost  (Day 85) 
 The maximum over baseline  on either Day 29 or 85 (post-priming response) 
 The maximum over pre-boost  (Day 85) on any of the Days 113, 169, or 254 
(post-boost response) 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 42  The maximum during  the study. 
 The Geometric Mean Titer (GMT) against each pertuss is antigen (PT, FHA, PRN, FIM 
2/3, and BPZE1 whole cell extract): 
 On Days 29, 85, 113, 169, and 254 
 The maximum on Day 29 or 85 ( after priming  dose) 
 The maximum after Days 113, 169, or 254 ( after boosting  dose) 
 The maximum during  the study. 
2.5.2  Secondary Mucosal Immunogenicity Endpoints 
The secondary mucosal immunogenicity S-IgA ELISA en dpoints (nasal mucosal secretion 
sampling) of this study are: 
 Proportion of subjects who achieve seroconversion a gainst any pertussis-specific antigen 
(PT, PRN, FHA, FIM 2/3, or BPZE1 whole cell extract ) over baseline: 
 At least 1 antigen on each  of the Days 29, 78, 113, 169, or 254 
 At least 1 antigen on any  of the Days 29, 78, 113, 169, or 254 
 At least any  1 antigen on all Days 29, 78, 113, 169, and 254. 
 Proportion of subjects who achieve seroconversion a gainst BPZE1 whole cell extract 
over baseline: 
 On either  Day 29 (prime) or 113 (boost) 
 On both  Days 29 (prime) and 113 (boost). 
 Proportion of subjects who achieve seroconversion a gainst aP antigens PT, FHA, and 
PRN over baseline: 
 On either  Days 29 (prime) or 113 (boost) 
 On both  Days 29 (prime) and 113 (boost). 
 Proportion of subjects who achieve seroconversion f or any 2 or more pertussis antigens 
(PT, PRN, FHA, or BPZE1 whole cell extract) over ba seline: 
 On each  of Days 29, 78, 113, 169, or 254 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 43  On any  of Days 29, 78, 113, 169 or 254 
 At least the same 2 antigens  on all Days 29, 78, 113, 169, and 254. 
 Proportion of subjects who demonstrate boosting aga inst each pertussis antigen (PT, 
FHA, PRN, FIM 2/3, and BPZE1 whole cell extract) on  Day 113. Boost is defined as at 
least a 2-fold increase from pre-boost sample taken  at Day 78.  
 The GMFR against each pertussis antigen (PT, FHA, P RN, FIM 2/3, and BPZE1 whole 
cell extract): 
 On Days 29, 78, 113, 169, and 254 over baseline  (Day 1) 
 On Days 113, 169, and 254 over pre-boost  (Day 78) 
 The maximum over baseline  on either Day 29 or 78 (post-priming response) 
 The maximum over pre-boost  (Day 78) on any of the Days 113, 169, or 254 
(post-boost response) 
 The maximum during  the study. 
 The GMT against each pertussis antigen (PT, FHA, PR N, FIM 2/3, and BPZE1 whole 
cell extract): 
 On Days 29, 78, 113, 169, and 254 
 The maximum on Days 29 or 78 ( after priming  dose) 
 The maximum after Days 113, 169, or 254 ( after boosting  dose) 
 The maximum during  the study. 
2.5.3  Secondary Colonization Endpoints 
 Proportion of subjects with positive B. pertussis  by bacterial culture of nasal sample 
collected on each day and on any day (Days 92, 96, and 113). 
 B. pertussis colony counts on each day (Days 92, 96, a nd 113).  
 Number of subjects who remain culture positive for B. pertussis  at Days 78 (following 
priming) and 254 (following boost).  
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 44 2.5.4  Secondary Safety Endpoints 
 Unsolicited AEs (eg, treatment-emergent AEs, SAEs, and suspected unexpected serious 
adverse reactions [SUSARs]) collected for 28 days f ollowing each vaccination by 
Medical Dictionary for Regulatory Activities (MedDR A) classification and severity 
score. 
 Unsolicited AEs related to vaccination through Day 113 by MedDRA classification and 
severity score. 
 Serious AEs through 6 months following the last vac cination (or until resolved or stable) 
by MedDRA classification, relatedness, and severity  score. 
 Vital sign measurements with severity scoring immed iately following vaccination. 
2.6  Exploratory Endpoint 
 Cell-mediated (eg, B cell, CD4 T lymphocytes + T ce ll, CD8 T lymphocytes + T cell) 
responses (eg, cell staining, cytokine production) following stimulation of PBMC 
collected at baseline, and 8 days post-vaccination (prime and boost) to pertussis-specific 
antigens. Results expressed both as absolute values  and fold over baseline (per specific 
assay characteristics). 
 Following the outcomes of the primary and secondary  analyses, additional exploratory 
endpoints may be tested for systemic or nasal mucos al immunogenicity (IgG or IgA) 
responses at any time point collected and not alrea dy performed in the primary or 
secondary analysis sets. 
 The GMT, expressed for serum IgG ELISA against teta nus and diphtheria on Days 29 
and 113. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 45 3 Investigational Plan 
3.1  Study Design 
This is a multi-center, randomized, placebo-control led, and observer-blinded trial with a 
6-month safety follow-up after the last vaccination . After signing the informed consent form 
(ICF), subjects will be enrolled in the trial and s creened over a window of 30 days; screening 
will include obtaining a nasal sample for mucosal p ertussis immune status. Subjects will also 
be asked to provide a signed ICF for the use of sam ples for further pertussis-specific testing 
or assay development. On Day 1, eligible subjects w ill be randomized to 1 of 4 treatment 
arms and receive BPZE1 intranasal vaccine or formul ation buffer for injection (placebo) (via 
the VaxINator atomization device) and a licensed aP  comparator vaccine (ie, Boostrix) or 
sterile normal saline (placebo), given by IM inject ion. To maintain the blind throughout the 
trial period, placebo vaccination via intranasal an d IM routes, using formulation buffer and 
normal saline, respectively will be included, and u nblinded pharmacy staff will manage 
vaccine logistics, preparation, and (if needed) adm inistration but will not be involved in 
study-related assessments or have subject contact f or data collection after study vaccine 
administration. Approximately 300 subjects will be randomly assigned 2:1 for the first 
(prime) vaccination with 200 subjects assigned to B PZE1 vaccination and 100 subjects 
assigned to Boostrix (aP vaccine) vaccination. Duri ng the second (boosting) vaccination, half 
of each of the treatment groups will be further ran domly assigned to receive BPZE1 or 
placebo resulting in a 2:2:1:1 randomization scheme  (Table 3-1).  
Table 3-1 Dosing Scheme 
Timing Day 1 Day 85 
Treatment Arm Nasal Vaccination IM Vaccination Nasa l Vaccination 
BPZE1 Placebo a Boostrix Placebo b BPZE1 Placebo a 
A (N  = 100)  X - - X X - 
B (N  = 100)  X - - X - X 
C (N = 50)  - X X - X - 
D (N = 50)  - X X - - X 
Abbreviation: IM, intramuscular. 
a  Intranasal application of 2 × 0.4 mL (0.4 mL per nostril) placebo (formulation buffer). 
b  IM injection of 0.5 mL placebo (normal saline) to  the deltoid region. 
As part of the screening procedures, all subjects w ill provide a nasal sample for 
determination of mucosal (S-IgA) pertussis antibody  status, with this sample collected at 
least 6 days prior to randomization. Day 1 vaccinat ion (primary) will be delivered by 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 46 intranasal application (BPZE1 or placebo) and by IM  injection into the deltoid (Boostrix [aP 
vaccine] or placebo), with subjects randomly assign ed to receive 1 of the 4 final treatment 
regimens. Nasal secretion sampling for mucosal anti body response (S-IgA ELISA) to 
pertussis-specific antigens will occur at baseline (screening) and on Days 29 and 78 
post-primary vaccination. Serum sampling for antibo dy response (IgA and IgA ELISA) will 
occur at baseline (Day 1 and prior to primary vacci nation) and on Days 29 and 85 (prior to 
boosting vaccination). Subjects will be tested for BPZE1 clearance (colonization) from the 
nasal tract via a standard nasal secretion sampling  on Day 78 and used for pertussis culture 
and colony count. There needs to be at least 6 days  between the nasal secretion sampling, 
which will occur at Visit 4 (Day 78), and the boost ing intranasal vaccination. The boosting 
vaccination visit (Day 85 [+7 days]) will consist o f all subjects receiving intranasal 
administration (BPZE1 or placebo) with half of the subjects who received BPZE1 for the 
primary vaccination receiving a second dose of BPZE 1 and the other half of subjects 
receiving placebo (Table 3-1). Similarly, half of t he subjects receiving Boostrix will receive 
BPZE1 and half will receive placebo. Colonization f ollowing the boosting vaccination will 
be measured on Days 92, 96, and 113 by standard nas al secretion sampling. Any subject who 
tested positive by pertussis culture on Day 113 wil l be retested on Day 254 or at the time of 
the end-of-study visit. Chronic carriage of BPZE1  has not been reported (ie, the majority of 
subjects have been clear at Day 29 and no subject h as had positive cultures at Day 46) and is 
therefore not expected. Any subject who remains pos itive at Day 254 will be provided a short 
course of azithromycin, which is clinically used to  eradicate B. pertussis  from the 
nasopharynx. Should a subject be allergic to azithr omycin, an appropriate antibiotic will be 
substituted that has effectiveness against B. pertussis . Mucosal (S-IgA ELISA) and serum 
response (IgG and IgA ELISA) to pertussis-specific antigens after boosting will be tested on 
Days 113, 169, and 254.  
The first 48 subjects randomly assigned will be des ignated the safety lead-in cohort and will 
be sequentially enrolled by escalating dose. The fi rst 24 subjects will be randomly assigned 
as noted above in a ratio of 2:1 to receive active product of either an intranasal dose of 
10 7 CFU of BPZE1 or IM Boostrix. These subjects will b e followed through Day 8 with 
safety laboratory tests, reactogenicity, and AE ass essments with daily review by the medical 
monitory for activation of any halting rule. Follow ing accumulation of all safety data through 
Day 8 post-vaccination, the 24 additional subjects will be randomly assigned 2:1 to receive 
active products of either an intranasal dose of 10 9 CFU of BPZE1 or IM Boostrix. To 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 47 maintain the blind for intranasal and IM administer ed products, all subjects will receive 
appropriate placebo vaccinations. All safety lead-i n subjects will have safety laboratory 
testing at baseline (screening), and on Days 8, 85 (prior to vaccination), and 92. The medical 
monitor has the authority to request a review by th e SMC should a halting rule be initiated or 
there are any other safety concerns. The SMC will c onvene after the subjects in the entire 
safety lead-in cohort (both dose levels) have compl eted Day 8 (Visit 2) and will review all 
safety data through Day 8 (reactogenicity and safet y laboratory results) and any AEs which 
have occurred since study initiation. The SMC will be authorized to allow the remainder of 
the subjects to be randomly assigned (see Table 3-2 ). The randomization scheme for the 
safety lead-in will follow the same scheme as the f ull cohort for the second vaccination 
(keeping at either 10 7 CFU or 10 9 CFU based on initial dosing assignment) such that half the 
BPZE1 and half the Boostrix vaccinated subjects wil l receive intranasal BPZE1 vaccination 
on Day 85 and the other half will receive placebo. 
Table 3-2 Dosing and Safety Lead-In Cohort 
BPZE1 
Dose BPZE1 Boostrix Trigger to advance Review Process Ad vancing to 
10 7 N = 16 N = 8 Day 8 safety on 10 7 dosing 
cohort  Pause rules; daily 
medical monitor reviews  10 9 safety lead-in 
10 9 N = 16 N = 8 Day 8 safety on full safety 
lead-in cohort; all adverse 
events  to date  Safety Monitoring 
Committee review Full cohort 
All subjects will be monitored for 60 minutes after  vaccine administration on Days 1 and 85. 
After the subjects have been monitored for 60 minut es post-vaccination, vital signs will be 
collected and a post-vaccination examination for re actogenicity (local, nasal/respiratory, and 
systemic) with toxicity grade will be completed.  
Subjects will receive a daily subject diary on Days  1 and 85 after each vaccination. All 
subjects will record reactogenicity in the daily su bject diary starting the same day of the 
primary (Day 1) and boosting (Day 85) vaccinations and for 7 additional days (not counting 
vaccination day). For primary vaccination site-spec ific local (arm), nasal/respiratory, general 
systemic reactogenicity reactions, and other unsoli cited symptoms/complaints (including 
start and stop dates) will be recorded and standard  toxicity grading will be applied by the 
investigator at the next visit (Visit 2). For the b oost vaccination, nasal/respiratory, general 
systemic reactogenicity reactions, and other unsoli cited symptoms/complaints (including 
start and stop dates) will be recorded and standard  toxicity grading will be applied by the 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 48 investigator at the next visit (Visit 6). The clini cal staff will review the information from the 
subject diaries with the subjects on Days 8 and 92 (Visits 2 and 6). Should any reactogenicity 
event extend beyond 7 days post-vaccination and be clinically significant by toxicity grade 1 
or greater, then it will be entered as an AE with t he same start date as the reactogenicity event 
and followed to resolution. 
All AEs will be monitored through 28 days after the  primary and boosting vaccinations. 
Unsolicited AEs related to vaccination will be moni tored through Day 113 (unless resolved 
or felt to be stable at an earlier date). Serious A Es will be monitored to the end of the study. 
The primary database lock will occur on Day 113, an d all data collected through Day 113 
will be included in the clinical study report (CSR)  and submitted to regulatory authorities. A 
subsequent longer-term safety follow-up, including longer-term persistence of immune 
responses, will occur through Day 254. These data w ill be provided, following a second 
database lock, in an addendum to the CSR. Subjects will return to the clinical site on Day 
254 (±15 days) for end-of-study procedures. 
A subset of no more than 60 subjects (randomly assi gned to the 10 9 CFU dose) will opt in to 
provide blood samples for PBMCs harvested on Days 1 , 8, and 92. 
Blood or blood cell samples may be stored frozen by  ILiAD or companies working for 
ILiAD for up to 10 years. 
3.1.1  Rationale of Study Design 
In order to advance BPZE1 into later stage licensur e trials, demonstration of an adequate 
immune response (mucosal and/or serum immunity) is necessary. As BPZE1 is a mucosal 
immunogen first and foremost, the IgA response is l ikely to be of key importance. Since 
regulators are accustomed to seeing the IgG respons e and IgG is known to be important for 
long-term protection against disease, this paramete r will also be assessed. In addition, 
demonstrating boosting and persistence of the immun e response with BPZE1 is critical. As 
aP vaccines are given as boosters to the adult popu lation, describing the immune response to 
BPZE1 following aP vaccination is of interest. Unde rstanding these responses relative to 
subject’s baseline mucosal and serum immunity is of  interest. The common pertussis 
antigens found in acellular products (PT, PRN, FHA,  and FIM 2/3) will be measured in 
serum samples (IgG and IgA) and a specific whole ce ll pertussis ELISA (based on BPZE1) 
will be measured in mucosal (S-IgA) and serum (IgG) . As the concentration of individual 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 49 antigens is vastly reduced in BPZE1 compared to aP vaccines, it is not anticipated that 
BPZE1 will have the same magnitude of immune respon se to the antigens found in acellular 
products. However, demonstration of a measurable re sponse akin to that seen with whole cell 
pertussis vaccines is anticipated and a measurable response to a whole cell pertussis ELISA 
provides additional immunological evidence. Develop ment of assays for additional markers 
of immunity may be needed. 
Nasal vaccination with BPZE1 has been shown to indu ce temporary nasal colonization 
followed by clearance, which is thought to be the r esult of development of mucosal 
immunity. The level of colonization/clearance follo wing a 2-course vaccination series is of 
interest using this higher dose of BPZE1 and it is anticipated that prior vaccination with 
BPZE1 will result in rapid mucosal immune response to a second vaccination (boosting) and 
may avert/reduce colonization at the time of boosti ng. It is anticipated that prior vaccination 
with aP will not induce the same protection against  colonization as compared to prior 
vaccination with BPZE1 and therefore a greater prop ortion of subjects will become colonized 
following boosting with BPZE1. Prior immunization w ith aP may result in a boosted serum 
immune response (IgG) to the pertussis antigens fou nd in Boostrix when subjects then 
receive BPZE1. Whether prior aP immunization can al so enhance the serum IgA response to 
these pertussis antigens following BPZE1 vaccinatio n is uncertain. Immunization with 
BPZE1 should result in a measurable whole cell pert ussis antibody response (IgG and IgA). 
A second vaccination with BPZE1 is expected to boos t this immunological response. 
However, it is not anticipated that aP would induce  a measurable whole cell pertussis 
response. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 50 4 Subject Selection and Withdrawal Criteria 
4.1  Selection of Study Population 
Approximately 300 subjects will be enrolled at 3 to  5 clinical sites in the United States. 
Subjects will be assigned to study vaccine only if they meet all the inclusion criteria and none 
of the exclusion criteria. 
Deviations from the inclusion and exclusion criteri a are not allowed because they can 
potentially jeopardize the scientific integrity of the study, regulatory acceptability, or subject 
safety. Therefore, adherence to the criteria as spe cified in the protocol is essential. 
4.1.1  Inclusion Criteria 
Each subject must meet all the following criteria t o be enrolled in this study: 
1.  Is a male or nonpregnant female 18 to 50 years of a ge, inclusive, on Day 1 (primary 
vaccination). 
2.  Is capable of understanding the written informed co nsent, provides signed and 
witnessed written informed consent, and agrees to c omply with protocol 
requirements. 
3.  Female subjects must be nonpregnant and nonlactatin g and meet 1 of the following 
criteria:  
a)  Postmenopausal (defined as 12 consecutive months wi th no menses without an 
alternative medical cause or documented plasma foll icle-stimulating hormone 
level in the postmenopausal range); 
b)  Surgically sterile (ie, hysterectomy, bilateral tub al ligation, or bilateral 
oophorectomy).  
NOTE: These procedures and laboratory test results must be confirmed by physical 
examination, or by subject recall of specific data and hospital/facility of procedure, or by 
medical documentation of said procedure. 
c)  Is of childbearing potential (defined as any female  who has experienced menarche 
and who is NOT permanently sterile or postmenopausa l), agrees to be 
heterosexually inactive from at least 21 days prior  to enrollment and through 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 51 3 months after the boosting vaccination or agrees t o consistently use any of the 
following methods of contraception from at least 21  days prior to enrollment and 
through 3 months after the boosting vaccination: 
i.  Condoms (male or female) with spermicide 
ii.  Diaphragm with spermicide 
iii.  Cervical cap with spermicide 
iv.  Intrauterine device 
v.  Oral or patch contraceptives 
vi.  Norplant ®, Depo-Provera ®, or other FDA-approved contraceptive 
method that is designed to protect against pregnanc y.  
NOTE: Periodic abstinence (eg, calendar, ovulation,  symptothermal, post-ovulation 
methods) and withdrawal are not acceptable methods of contraception. 
4.  Has a stable health status as assessed by the inves tigator, as established by physical 
examination, vital sign measurements, and medical h istory. 
5.  Has access to a consistent and reliable means of te lephone contact, which may be in 
the home, workplace, or by personal mobile electron ic device. 
6.  Is able to understand and comply with planned study  procedures. 
7.  Lives a reasonable distance from the clinical site to be able to travel to and from the 
clinical site for follow-up visits and agrees to go  to the clinical site for evaluation (or 
provide medical record access if evaluated elsewher e) in the event of an AE.  
8.  Agrees to stay in contact with the clinical site fo r the duration of the study, has no 
current plans to move from the study area, and prov ides updated contact information 
as necessary. 
4.1.2  Exclusion Criteria 
Subjects meeting any of the following criteria will  be excluded from the study: 
1.  History of being vaccinated in the past 5 years aga inst pertussis (subject recall). 
2.  Any significant past reaction to any component of B oostrix (at the discretion of the 
investigator). 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 52 3.  Subject reported diagnosis of pertussis in the past  10 years (must be laboratory 
confirmed or physician diagnosed from medical recor ds). 
4.  Vital signs by toxicity scoring >1 (may be repeated  once during the screening period 
to allow for inclusion and the most recent measurem ent taken at baseline). 
5.  Chronic illness being treated actively and with evi dence of recent intervention for 
worsening or fluctuating symptoms (at the discretio n of the investigator). 
6.  The subject has a history of active cancer (maligna ncy) in the last 10 years 
(exception is subjects with adequately treated non- melanomatous skin carcinoma, 
who may participate in the study). 
7.  Current use of any smoking products and unwillingne ss to refrain from the use of 
any smoking products from screening through 28 days  after the boosting 
vaccination. 
8.  Use of narcotic drugs, evidenced by urine toxicolog y screen or a history of 
drug/alcohol abuse within the past 2 years. 
9.  Has donated blood or suffered from blood loss of mo re than 450 mL (1 unit of 
blood) within 60 days prior to screening, or donate d plasma within 14 days prior to 
screening. 
10.  Receipt of immunoglobulin, blood-derived products, systemic corticosteroids, or 
other immunosuppressant drugs within 90 days prior to Day 1. 
11.  Asthma*, obstructive nasal canal, recurrent or acut e sinusitis or other chronic 
respiratory problems inclusive of the diagnosis of any significant pulmonary disease. 
*Asthma as diagnosed with spirometry showing revers ibility of disease and must 
meet at least Step 1 classification with current pr escription/use of medications to 
control symptoms (EPR-3 2007). 
12.  History of nasal surgery or Bell’s palsy. 
13.  Use of repeated nasal sprays, Neti pot, or nasal wa shing within the past 1 month 
(more than 2 times per week). Subjects must agree t o refrain from use of any of 
these modalities through Day 113. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 53 14.  A temporary exclusion to vaccinate if acute respira tory tract infection or rhinorrhea 
or temperature >100.4°F (no symptoms for 3 days pri or to Vaccination Day). 
Subjects may be vaccinated if they stay within the vaccination window (screening 
[30 days] or at the time of the booster [10 days]. 
NOTE: If a subject exceeds the screening window, th ey must be reconsented and 
screening must be reinitiated. 
15.  Use of corticosteroids in the respiratory tract (eg , nasal steroids, inhaled steroids) 
within 30 days prior to Day 1.  
16.  Receipt of a licensed vaccine within the last 30 da ys prior to Day 1 or planned 
vaccination during the active study conduct through  Day 113. In the case of seasonal 
influenza, vaccination should not be withheld and i s not contraindicated for subject 
participation. However, vaccination should be plann ed outside of a 30-day pre- and 
30-day post-vaccination window whenever possible. 
17.  Known hypersensitivity to any component of the stud y vaccines. 
18.  Participation in any other clinical trial for the t esting of an unlicensed product during 
the previous 6 months or planned during the study c onduct. 
NOTE: “Testing” is intended to mean receipt of an i nvestigational product. Subjects in 
long term safety follow-up studies where vaccinatio n has been completed greater than 6 
months prior to this study enrollment are allowed. 
19.  Inability to adhere to the protocol, including plan s to move from the area. 
20.  Personal history or family (first degree) history o f congenital or hereditary 
immunodeficiency.  
21.  Past or present infection with human immunodeficien cy virus, hepatitis B, or 
hepatitis C by screening test. 
22.  Any autoimmune or immunodeficiency disease/conditio n (inherited or iatrogenic). 
NOTE: Stable endocrine disorders that have a confir med autoimmune etiology (eg, 
thyroid, pancreatic) are allowed. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 54 23.  Any neurological disease or history of significant neurological disorder (eg, 
meningitis, seizures, multiple sclerosis, vasculiti s, migraines*, Guillain-Barré 
syndrome [genetic/congenital or acquired]).*Signifi cant neurological migraine 
includes frequent migraine (2 times a month or grea ter), migraine with aura or 
migraine with complications (status migraninosus, p ersist aura without infarction, 
infarction or aura triggered seizure defined by Int ernational Classification of 
Headache Disorders-3 [ICHD-3 2018]). 
24.  Any medical condition that, in the opinion of the i nvestigator, might interfere with 
the evaluation of the study objectives or might aff ect the safety of the individual, eg, 
major depression or history of suicidal attempt. 
25.  Toxicity grading >1 for screening laboratory test r esults for specific kidney, hepatic, 
and hematologic values for all subjects and in scre ening laboratory values for the 
safety cohort as indicated in Table 13-2 (may be re peated once during the screening 
period to allow for inclusion and the most recent m easurement taken at baseline). 
See Table 13-2 for specifically designed parameters .  
26.  Body mass index <17 kg/m 2 or >40 kg/m 2. 
27.  Frequent contact with children less than 1 year of age (parent, childcare worker, 
nurse, etc.) or residence in the same household as persons with known 
immunodeficiency including persons on immunosuppres sant therapy. 
28.  Study team member or first-degree relative of study  team member. 
4.2  Withdrawal of Subjects From Study Treatment and/or the Study 
The duration of the study is defined for each subje ct as the date signed written informed 
consent is provided through the last follow-up visi t on Day 254. 
4.2.1  Reasons for Withdrawal/Discontinuation 
Subjects may withdraw or discontinue from the study  at any time and for any reason without 
prejudice to their future medical care by the inves tigator or at the study center. Every effort 
should be made to keep subjects in the study. The r easons for subjects not completing the 
study will be recorded. A subject may be withdrawn from the study or study treatment (ie, no 
longer receive study vaccine) for any of the follow ing reasons: 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 55 1.  Failure to continue to meet the protocol inclusion or exclusion criteria. 
2.  Noncompliance with the protocol. 
3.  Serious or intolerable AE(s) that in the investigat or’s opinion requires withdrawal or 
discontinuation from the study.  
4.  The subject has laboratory safety results that reve al clinically significant 
hematological or biochemical changes from the basel ine values. 
5.  The subject has symptoms or an intercurrent illness  not consistent with the protocol 
requirements or that justify withdrawal or disconti nuation. 
6.  The subject is lost to follow-up. 
7.  Other reasons (eg,  development of contraindication s of use of study drug, use of 
disallowed substances). 
8.  If pregnancy occurs further vaccination will be dis continued. 
9.  The subject withdraws consent or the investigator o r ILiAD Biotechnologies decides 
to discontinue the subject’s participation in the s tudy. 
The investigator will also withdraw a subject if IL iAD Biotechnologies terminates the study. 
Upon occurrence of a serious or intolerable AE, the  investigator will confer with the sponsor. 
If a subject is discontinued because of an AE, the event will be followed until it is resolved. 
Any subject may withdraw his or her consent at any time. 
4.2.2  Handling of Withdrawals 
Subjects are free to withdraw from the study or stu dy treatment at any time upon request. 
Subject participation in the study may be stopped a t any time at the discretion of the 
investigator or at ILiAD Biotechnologies request. 
Subjects who discontinue study treatment or active participation in the study will no longer 
receive study vaccination but will continue to be f ollowed and are not considered withdrawn. 
When a subject withdraws from the study, the reason (s) for withdrawal shall be recorded by 
the investigator on the relevant page in the electr onic case report form (eCRF).  
All subjects who discontinue from study treatment p rematurely will follow the same visit 
schedule as other subjects without further vaccinat ion. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 56 Whenever possible, all subjects who discontinue fro m the study prematurely will stay in the 
study for safety reasons and will follow the schedu le of events (Table 13-1) if they have 
received vaccination. Subjects who fail to return f or final assessments will be contacted by 
the clinical site in an attempt to have them comply  with the protocol. A subject will not be 
considered lost to follow-up until every attempt to  contact the subject has been made, at 
minimum 2 (documented) phone calls, followed by a r egistered letter. Every effort should be 
made to collect safety data on subjects through the  end-of-study visit. 
It is vital to obtain follow-up data on any subject  withdrawn from the study or study vaccine 
(ie, no longer receiving study vaccination) because  of an AE or serious AE (SAE). In every 
case, efforts must be made to undertake protocol-sp ecified safety follow-up procedures. 
4.2.3  Replacements 
Subjects who withdraw, are withdrawn or terminated from this study, or are lost to follow-up 
after signing the ICF but before receipt of any stu dy vaccine may be replaced. Subjects who 
receive the study vaccine and subsequently withdraw , are discontinued from receiving further 
vaccination, are terminated from the study, or are lost to follow-up will not be replaced. 
5 Study Treatments 
5.1  Method of Assigning Subjects to Treatment Groups 
Subjects will be randomly assigned to 1 of 4 treatm ent arms, in a 2:2:1:1 ratio, as presented 
in Table 3-1. An interactive response technology wi ll be used to administer the randomization 
schedule centrally. Biostatistics will generate the  randomization schedule using SAS ® 
software Version 9.3 or later (SAS Institute Inc, C ary, North Carolina) for the interactive 
response technology, which will link sequential sub ject randomization numbers to treatment 
codes. The randomization schedule will be created b y the dedicated randomization team, 
stored in a separate project area, and will be blin ded to the project team with the exception of 
the unblinded pharmacy staff who will manage vaccin e logistics, preparation, and 
administration, but will not be involved in study-r elated assessments or have subject contact 
for data collection following study vaccine adminis tration. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 57 5.2  Treatments Administered 
Subjects in Treatment Arm A (N = 100) will receive an intranasal application of 2 × 0.4 mL 
(0.4 mL per nostril containing half the dose 5 × 108 bacteria to give a total dose of 10 9 CFU) 
BPZE1 and an IM injection of 0.5 mL placebo (steril e normal saline) to the deltoid region on 
Day 1 and an intranasal application of 2 × 0.4 mL ( 0.4 mL per nostril containing half the dose 
5 × 10 8 bacteria to give a total dose of 10 9 CFU) BPZE1 on Day 85. Note: the first 
24 subjects will be assigned to the 10 7 CFU dose. 
Subjects in Treatment Arm B (N = 100) will receive an intranasal application of 2 × 0.4 mL 
(0.4 mL per nostril containing half the dose 5 × 108 bacteria to give a total dose of 10 9 CFU) 
BPZE1 and an IM injection of 0.5 mL placebo (steril e normal saline) to the deltoid region on 
Day 1 and an intranasal application of 2 × 0.4 mL ( 0.4 mL per nostril) placebo (formulation 
buffer) on Day 85. Note: the first 24 subjects will  be assigned to the 10 7 CFU dose.  
Subjects in Treatment Arm C (N = 50) will receive a n intranasal application of 2 × 0.4 mL 
(0.4 mL per nostril) placebo (formulation buffer) a nd an IM injection of 0.5 mL Boostrix (aP 
vaccine, manufactured by GlaxoSmithKline, Research Triangle Park, North Carolina) to the 
deltoid region on Day 1 and an intranasal applicati on of 2 × 0.4 mL (0.4 mL per nostril 
containing half the dose 5 × 10 8 bacteria to give a total dose of 10 9 CFU) BPZE1 on Day 85. 
Note: the first 24 subjects will be assigned to the  10 7 CFU dose. 
Subjects in Treatment Arm D (N = 50) will receive a n intranasal application of 2 × 0.4 mL 
(0.4 mL per nostril) placebo (formulation buffer) a nd an IM injection of 0.5 mL Boostrix (aP 
vaccine), to the deltoid region on Day 1 and an int ranasal application of 2 × 0.4 mL (0.4 mL 
per nostril) placebo (formulation buffer) on Day 85 . Note: the first 24 subjects will be 
assigned to the 10 7 CFU dose. 
The dose of BPZE1 active ingredient will be adminis tered to the subject within 60 minutes of 
removal from the freezer. One milliliter of WFI wil l be used to reconstitute the 1 mL vial of 
lyophilized BPZE1, but only 0.8 mL of vaccine will be withdrawn for administration into 
both nostrils. Following reconstitution, the VaxINa tor will be attached to the syringe, and 
0.4 mL volume will be administered to each nostril.  In the case of placebo nasal vaccination, 
a similar volume of WFI will be reconstituted into a vial containing only lyophilized buffer, 
followed by 0.4 mL volume administered into each no stril with the vaccinator. The 
VaxINator provides a uniform, controlled delivery, which allows the vaccinator to accurately 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 58 deliver 0.4 mL of vaccine to the initial nostril an d then administer the remaining 0.4 mL to 
the opposite nostril.  
The study vaccine will be labeled according to manu facturer specifications and include the 
statement “Caution: New Drug – Limited by Federal L aw to Investigational Use.” 
5.3  Identity of Investigational Product 
The BPZE1 investigational vaccine is for intranasal  administration and is an off-white 
lyophilized cake that contains genetically modified , live B. pertussis  strain BPZE1 bacteria in 
lyophilization buffer.  
ILiAD Biotechnologies will provide the CRO with the  investigational vaccine and 
lyophilized buffer and the CRO will ensure proper l abelling and distribution to the clinical 
sites. 
The following supplies will be used for vaccination  in the study: 
Product Dosage and Route of Administration: 
BPZE1 2 × 0.4 mL (0.4 mL per nostril containing 
half the dose 5 × 10 8 bacteria to give a total 
dose of 10 9 CFU) administered intranasally 
by syringe + VaxINator 
aP (Boostrix vaccine; manufactured by 
GlaxoSmithKline) 0.5 mL administered by IM injection to the 
deltoid region as active control 
Intranasal placebo 2 × 0.4 mL (0.4 mL per nostril) reconstituted 
lyophilized buffer administered intranasally 
by syringe + VaxINator 
IM placebo 0.5 mL sterile normal saline USP 
administered by IM injection to the deltoid 
region 
Abbreviations: aP, acellular pertussis; CFU, colony -forming units; IM, intramuscular; USP, United Stat es 
Pharmacopeia. 
The intranasal placebo consists of lyophilized buff er diluted with sterile WFI which, is the 
same constituents in the same quantities as the BPZ E1 investigational vaccine, absent the 
attenuated B. pertussis  cells. The IM placebo is sterile normal saline (eg , normal saline).  
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 59 Each vaccination with BPZE1 or Boostrix will utiliz e a single vial/syringe of product for 
each single use (1:1 assignment from study drug acc ountability). See pharmacy manual for 
specifics on product preparation. 
5.3.1  Study Drug Packaging and Storage 
The primary packaging for BPZE1 is a sterile glass 2R DIN vial with a chlorobutyl 
lyophilization stopper. The vial closure system is a combination of the stopper and the 
aluminum cap. The vials are crimped directly after the lyophilization process using the 
automated Fill & Finish unit that filled the vials with 1.0 mL suspension. The intranasal 
placebo dose contains the lyophilized buffer (ie, t he vaccine formulation without the BPZE1 
attenuated bacteria) and packaged in similar fashio n. 
Sufficient supplies of 1 vial for each subject in t he clinical trial will be provided, with 
approximately 30% spare vials, packaged in a box of  49 vials for the BPZE1 drug product 
and 41 vials per box for the placebo. The vials and  the boxes will be labeled with the required 
information applicable to investigational vaccine o r placebo product used in clinical trials. 
The boxes either contain the vaccine or the placebo  (lyophilized buffer only).  
The 18G (or larger) needles, WFI, and syringes capa ble of holding 1 mL WFI used to 
reconstitute the investigational vaccine or placebo  (formulation buffer) vials will be stored 
separately from the investigational vaccine vials a t ambient temperature.  
Boostrix will be procured from commercial stock and  supplied as either single dose vials or 
prefilled syringes containing a 0.5 mL suspension f or injection. The IM placebo is sterile 
normal saline United States Pharmacopeia (from a co mmercial supplier) and is supplied in a 
similar fashion. 
Vaccines and placebos must be stored in a secure ar ea (eg, locked room or locked 
refrigerator), protected from light and moisture as  required by manufacturer. Vaccine will be 
shipped from ILiAD’s European contract manufacturin g organization to the CRO’s 
repository and distribution center and should be st ored at –20°C or below prior to shipping to 
the clinical sites, where the vaccine will be store d at –10°C or below. Clinical sites will store 
the vaccine in order to maintain viability of BPZE1  prior to reconstitution with WFI. The 
exposure of reconstituted BPZE1 to room temperature  prior to vaccination should not exceed 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 60 60 minutes. A detailed description regarding the st orage, reconstitution, and handling the 
investigational vaccines will be in the Pharmacy Ma nual. 
Boostrix should be stored at 2°C to 8°C.  
5.3.2  Investigational Product Accountability 
The investigator will maintain accurate records of receipt of all study vaccine and placebo 
vials, including dates of receipt. In addition, acc urate records will be kept regarding when 
and how much study vaccine is dispensed and used by  each subject in the study. Reasons for 
departure from the expected dispensing regimen must  also be recorded. At the completion of 
the study, to satisfy regulatory requirements regar ding drug accountability, all study vaccine 
will be reconciled and retained or destroyed accord ing to applicable regulations. No study 
vaccine will be destroyed until authorized in writi ng by the sponsor. 
5.3.3  Other Supplies 
Other clinical supplies that will be provided to th e clinical sites for distribution to subjects 
include subject diaries, a measuring tool for measu ring injection site erythema and swelling, 
and a thermometer for measuring body temperature.  
A single VaxINator kit (sterile pouch containing a VaxINator atomization devise, a 1-mL 
single-use syringe, and other accessories not used in this protocol) is provided for each 
intranasal vaccination. The VaxINator boxes will be  labeled with the required information 
applicable to a medical device accessory, for clini cal trial investigational use only. The 
VaxINator is manufactured by Teleflex Medical. Tele flex has DMF #025388 for the 
VaxINator. The VaxINator is a conical shape plastic  component that Luer-locks onto a 1-mL 
syringe. The VaxINator atomizes the liquid vaccine as it exits the syringe. The conical shape 
forms a plug in the nostril and high applied-pressu re atomizes the liquid into a fine mist. 
Kits for serum immune collection, mucosal immune co llection, PBMCs and mucosal 
pertussis culture will all be provided and in suffi cient quantity to allow for each subject 
sample collection. Bar coding will be applied to al low for sample tracking at the time of 
collection and throughout storage, transport, and t esting. 
Adequate supplies for immunization of individuals i ncluding, 18G (or larger) needles for 
injection, syringes, normal saline, nasal vaccinato rs, and blinding tape will be supplied. The 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 61 WFI will be provided for reconstituting the investigational vaccine and placebo vials for 
nasal immunization and will be stored separately fr om the investigational vaccine vials, at 
ambient temperature in a secure area.  
5.4  Overdose Management 
An overdose is any dose of study treatment given to  a subject or taken by a subject that 
exceeds the dose described in the protocol. Any ove rdose, with or without associated AEs, 
must be promptly reported to the CRO’s pharmacovigi lance reporting center. In case of any 
AEs associated with the overdose, these should be r eported on relevant AE/SAE sections in 
the eCRF. Any overdose should be recorded as a prot ocol violation and promptly reported to 
the sponsor. No overdoses are expected as the vacci ne and adjuvant will be administered by 
clinical staff. 
5.4.1  Treatment of Overdose 
Treatment of overdose would include supportive and symptomatic care, according to the 
standards of care at the site. The investigator sho uld promptly notify the medical monitor 
about the overdose and seek his/her input on the me dical management, as needed. 
5.5  Blinding 
This is an observer-blinded study. To maintain the blind, placebo vaccination via intranasal 
and IM routes will be included and unblinded pharma cy staff will manage vaccine logistic, 
preparation, and administration (when necessary) so  as to maintain the blind from the 
remainder of the study personnel and subjects. The pharmacy staff will not be involved in 
study-related assessments or have subject contact f or data collection following study vaccine 
administration. 
The full database lock will occur on Day 113 and al l data collected through Day 113 will be 
included in the CSR and submitted to regulatory aut horities. A subsequent longer-term safety 
follow-up, including longer-term persistence of imm une responses, will occur through 
Day 254. These data will be provided in an addendum  to the CSR. The clinical site study 
team directly participating in subject contact/care  will remain blinded to the treatment 
assignment during this extended safety follow-up pe riod. All unblinded data analyses prior to 
full database lock on Day 113 will be handled by th e unblinded team of statisticians and 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 62 programmers. A strict firewall between the blinded and unblinded teams will be maintained 
during study conduct. 
5.5.1  Breaking the Blind Due to Medical Emergency 
A subject’s treatment assignment will not be broken  until the end of the study for the clinical 
site study team unless medical treatment of the sub ject depends on knowing the study 
treatment the subject received. In the event that t he blind needs to be broken because of a 
medical emergency, the investigator may unblind an individual subject’s treatment allocation.  
As soon as possible, the investigator should first contact the medical monitor to discuss the 
medical emergency and the reason for revealing the actual treatment received by that subject. 
The treatment assignment will be unblinded through interactive response technology. 
Reasons for treatment unblinding must be clearly ex plained and justified in the eCRF. The 
date on which the code was broken together with the  identity of the person responsible must 
also be documented. 
5.6  Treatment Compliance 
The study vaccination will be administered to maint ain the blind to site personnel conducting 
subject assessments. The location (in case of IM ad ministration, right or left arm), date, and 
timing of all product administrations will be recor ded in the subjects’ eCRF. Compliance will 
be determined by the number and percentage of subje cts who receive study vaccination. Any 
deviations from the dosing schedule outside the def ined visit windows (Table 13-1) will be 
flagged in the clinical database.  
5.7  Prior Vaccinations and Concomitant Therapy 
Administration of medications, therapies, or vaccin es will be recorded in the eCRF. 
Concomitant medications will include all medication s (including vaccines) taken by the 
subject from the time of signing the ICF through 28  days after the boosting vaccination (or 
through the early termination visit if prior to tha t time). Intake will include whether there was 
knowledge of past pertussis vaccination and (when a vailable) the year of receipt. Prescription 
and over-the-counter drugs will be included, as wel l as herbals, vitamins, and supplements. 
In addition, receipt of nonstudy vaccines will be s olicited through approximately 28 days 
after the boosting vaccination and reported in the eCRF. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 63 Use of new medication should prompt evaluation for the presence of a new diagnosis of 
chronic medical disease or condition. Medications t hat might interfere with the evaluation of 
the study vaccines should not be used during the st udy-reporting period unless clinically 
indicated as part of the subject’s health care. New  medications may indicate a new onset 
medical condition. As an example, the use of a bron chodilator medication due to wheezing 
(new prescription) will be used along with signs an d symptoms to define a medically 
significant wheezing AE. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 64 6 Study Assessments and Procedures 
Before performing any study-related procedures, the  investigator will explain the study to 
potential subjects and all potential subjects will be given an ICF to read and sign. Subjects 
will have the opportunity to have any questions ans wered before signing the ICF. The 
investigator must address all questions raised by t he subject. The investigator or designee 
will also sign the ICF and a copy of the ICF will b e given to the subjects. In addition, 
subjects will be asked to provide a signed informed  consent for the use of samples for further 
pertussis-specific testing or assay development. Th e subjects will also be informed that a 
urine drug screen may be performed, at the discreti on of the investigator, on any subject who 
experiences an AE. The schedule of events by study visit is shown in Table 13-1. 
6.1  Demographic and Baseline Data 
Demographic and baseline data such as date of birth  (day, month, and year), sex, race, 
ethnicity, weight, height, and body mass index shou ld be collected at screening and recorded 
in the subject’s eCRF. 
6.2  Medical History 
A complete medical history (including prior and con comitant medical conditions, 
surgeries/significant procedures for medical condit ions [eg, endoscopy, uterine ablation] 
history of past tobacco use) will be collected at s creening. If the year of past pertussis 
vaccination is known by the subject this will be en tered as part of the medical history (eg, 
Tdap booster). 
6.2.1  Concomitant Medication 
Concomitant medications include all known medicatio ns (including herbal supplements, 
multivitamins and over-the-counter medications) tak en by the subject from the time of 
signing the informed consent through 28 days after the boosting vaccination (or through early 
termination visit if prior to that time). Concomita nt medications received associated with an 
SAE will be collected throughout the study period. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 65 6.3  Safety Assessments 
Safety assessments for all subjects will include th e following: vital sign measurements, 
targeted symptom directed physical examination, cli nical safety laboratory tests (screening 
for all subjects, safety cohort to have additional testing), reactogenicity (post-vaccination), 
AEs and the occurrence of SAEs. These assessments a re detailed in Sections 6.3.1  through 
6.3.6 .  
The first 48 subjects randomly assigned will be des ignated the safety lead-in cohort and will 
have additional safety laboratory testing performed  on Days 8, 85 (prior to vaccination), and 
92. 
6.3.1  Vital Sign Measurements 
Vital sign measurements will include oral temperatu re, pulse rate, and diastolic and systolic 
blood pressure (after subject is seated for at leas t 5 minutes). Subjects must not eat or drink 
anything hot or cold within 10 minutes prior to tak ing oral temperature. Vital signs will be 
toxicity graded per the FDA toxicity (Table 13-3). 
Vital signs will be collected at screening and on D ays 1 (before vaccine administration and 
60 minutes [±15 minutes] after vaccine administrati on [before subject is discharged]), 8, 29, 
85 (before vaccine administration and 60 minutes [± 15 minutes] after vaccine administration 
[before subject is discharged]), 92, 96, and 113.  
6.3.2  Post-vaccination Evaluation 
On Days 1 and 85, subjects will be monitored for 60  minutes after vaccine administration. 
Details regarding collecting and reporting site-spe cific local and nasal/respiratory and 
systemic reactogenicity symptoms are presented in Section 6.3.5.3 . Subject diaries will be 
distributed according to Table 13-1 and will be use d to record site-specific local, 
nasal/respiratory, and systemic reactions. Solicite d local, nasal/respiratory, and systemic 
reactogenicity will be graded by the investigator a t the return visit (Days 8 and 92). Should 
any reactogenicity event extend beyond 7 days post- vaccination and be clinically significant 
by toxicity grade 1 or greater, then it will be ent ered as an AE with the same start date as the 
reactogenicity event and followed to resolution. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 66 In addition, a measuring tool for measuring injecti on site erythema and swelling and a 
thermometer for measuring body temperature will als o be distributed.  
After the subject has been monitored for 60 minutes  after vaccination, the following 
evaluations will be performed: 
1.  Obtain vital sign measurements (oral temperature, p ulse rate, and diastolic and 
systolic blood pressure) at 60 minutes (±15 minutes ) after vaccination. Vital signs 
will be toxicity graded per the FDA toxicity (Table  13-3). 
2.  Complete an injection site examination for reactoge nicity (local, nasal/respiratory, 
and systemic) and toxicity grade (see Section 6.3.5.3 ) at 60 minutes (±15 minutes) 
after vaccination. 
6.3.3  Complete Physical Examination 
A full physical examination will be completed at sc reening and will include the following: an 
assessment of skin, head, ears, eyes, nose, throat,  neck, thyroid, lungs, heart, abdomen, 
lymph nodes, musculoskeletal system/extremities, an d neurological system. Height and 
weight will be measured at the screening visit only . 
A targeted or symptom-directed physical examination  will be performed as mentioned in the 
schedule of events for all subjects on Days 1, 8, 2 9, 85, 92, 96, and 113 (Table 13-1). On 
Days 1 and 85, this physical examination is done be fore vaccination. For unscheduled visits, 
targeted symptom directed physical examinations wil l be performed at the discretion of the 
investigator, if necessary, to evaluate AEs or clin ical laboratory abnormalities. 
6.3.4  Clinical Safety Laboratory Tests 
Clinical safety laboratory tests will include the f ollowing and will be collected as mentioned 
in the schedule of events for all subjects at scree ning and for the safety lead-in cohort at 
screening, and Days 8, 85 (prior to vaccination), a nd 92 (Table 13-1): 
 Hematology: hemoglobin, white blood cell count and differential, and platelet count. 
 Chemistry panel: sodium, potassium, glucose (random ), blood urea nitrogen, creatinine, 
calcium, albumin, total protein, bilirubin, alanine  aminotransferase, and aspartate 
aminotransferase 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 67  Coagulation: Prothrombin time/international normali zed ratio and partial thromboplastin 
time 
For the full cohort, toxicity scoring of >1 for hem oglobin, white blood count, platelets, 
creatinine, alanine aminotransferase, aspartate ami notransferase, bilirubin, prothrombin time 
and partial thromboplastin time will be used as exc lusionary criteria (Table 13-2). For the 
safety cohort all laboratory tests noted in Table 1 3-2 with toxicity score >1 will be used as 
exclusionary criteria. For the safety cohort being followed with additional scheduled safety 
labs, should any laboratory value result in a grade  3 or greater toxicity score this lab must be 
entered as an adverse event and followed with retes ting and observing for resolution or new 
clinical baseline. In the case of an alternative ex planation for the abnormal laboratory (eg, 
urinary tract infection with an elevated WBC) the i llness should be the AE classification. 
Investigators should determine if any laboratory va lues resulting in a grade 2 toxicity score 
should be entered as an AE, with repeat testing bas ed on clinical judgement and the 
laboratory value of concern. 
6.3.4.1  Serology 
Serology testing will be collected at screening and  will include hepatitis B, hepatitis C, and 
human immunodeficiency virus.  
6.3.4.2  Urine Drug Screen 
A urine drug screen will be performed at screening and will include the following 
non-prescription drugs of abuse: opiates, cocaine, phencyclidine, amphetamines, 
benzodiazepines, and methadone.  
At the discretion of the investigator a urine drug screen may be performed on any subject 
who experiences an AE. 
6.3.4.3  Urine Pregnancy Test 
For female subjects of childbearing potential, a ur ine pregnancy test will be performed at 
screening and prior to vaccination on Days 1 and 85 . 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 68 6.3.5  Adverse Events 
6.3.5.1  Definitions of Adverse Events 
The investigator is responsible for reporting all A Es that are observed or reported during the 
study, regardless of their relationship to study va ccination or their clinical significance. 
An AE is defined as any untoward medical occurrence  in a subject enrolled into this study 
regardless of its causal relationship to study vacc ination. Subjects will be instructed to 
contact the investigator at any time after randomiz ation if any symptoms develop.  
6.3.5.2  Serious Adverse Events 
An SAE is defined as any event that 
 results in death 
 is immediately life threatening 
 requires inpatient hospitalization or prolongation of existing hospitalization 
 results in persistent or significant disability/inc apacity 
 is a congenital anomaly/birth defect 
Important medical events that may not result in dea th, be life threatening, or require 
hospitalization may be considered SAEs when, based upon appropriate medical judgment, 
they may jeopardize the subject or may require medi cal or surgical intervention to prevent 
one of the outcomes listed in this definition. Exam ples of such medical events include 
allergic bronchospasm requiring intensive treatment  in an emergency room or at home, 
blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse. 
At the discretion of the investigator, a urine drug  screen may be performed on any subject 
who experiences an SAE. 
6.3.5.3  Site-Specific and General Systemic Reactogenicity S ymptoms 
Subjects will receive a daily subject diary on Days  1 and 85 after each vaccination. All 
subjects will record reactogenicity in the daily su bject diary starting the same day of the 
primary (Day 1) and boosting (Day 85) vaccinations and for 7 additional days (after each 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 69 vaccination, not counting vaccination day). Reactog enicity events are common and known to 
occur following administration of these types of va ccinations. For primary vaccination site-
specific local (arm), nasal/respiratory, general sy stemic reactogenicity reactions, and other 
unsolicited symptoms/complaints, including start an d stop dates will be recorded and the 
investigator will apply a standard toxicology gradi ng at the subsequent visit (Table 6-1). For 
the boosting vaccination, nasal/respiratory, genera l systemic reactogenicity reactions, and 
other unsolicited symptoms/complaints, including st art and stop dates will be recorded and 
then toxicity graded by the investigator (Table 6-1 ). The clinical staff will review the 
information from the subject diary with the subject s on Days 8 and 92. The subject diary will 
be collected from the subjects and stored as a sour ce document. Should any reactogenicity 
event extend beyond 7 days post-vaccination and be clinically significant by toxicity grade 1 
or greater, then it will be entered as an AE with t he same start date as the reactogenicity event 
and followed to resolution. The following toxicity grading scales will be used to grade 
solicited local, nasal/respiratory, and systemic re actions:  
Table 6-1 Toxicity Grading Scales 
Local Reactogenicity Grading 
Local Reaction to 
Injectable Product  Mild (Grade 1)  Moderate 
(Grade 2)  Severe (Grade 3)  Potentially Life 
Threatening 
(Grade 4) 
Pain Does not interfere 
with activity Repeated use of 
nonnarcotic pain 
reliever >24 hours or 
interferes with 
activity Any use of narcotic 
pain reliever or 
prevents daily 
activity Emergency room 
visit or 
hospitalization 
Tenderness Mild discomfort to 
touch Discomfort with 
movement Significant 
discomfort at rest Emergency room 
visit or 
hospitalization 
Erythema/redness a 2.5 to 5 cm 5.1 to 10 cm >10 cm Necrosis or 
exfoliative 
dermatitis 
Induration/swelling b 2.5 to 5 cm and 
does not interfere 
with activity 5.1 to 10 cm or 
interferes with 
activity >10 cm or prevents 
daily activity Necrosis 
Nasal/Respiratory Reactogenicity Grading 
Local Reaction Mild (Grade 1) Moderate (Grade 2) Se vere (Grade 3) 
Runny nose Noticeable but does not 
interfere with daily 
activity Moderate discomfort that 
interferes with daily 
activity Significant 
discomfort/prevents daily 
activity or seeks medical 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 70 Nasal/Respiratory Reactogenicity Grading 
Local Reaction Mild (Grade 1) Moderate (Grade 2) Se vere (Grade 3) 
care 
Stuffy nose/congestion  Noticeable but does not 
interfere with daily 
activity  Moderate discomfort that 
interferes with breathing 
from nose  Unable to breathe through 
nose or seeks medical care  
Nasal pain/irritation  Noticeable but does not 
interfere with daily 
activity  Moderate discomfort that 
interferes with daily 
activity  Significant discomfort that 
prevents daily activity or 
seeks medical care  
Epistaxis Total duration of all 
episodes in a 24-hour 
period <30 minutes Total duration of all 
episodes in a 24-hour 
period >30 minutes Any bleeding that required 
visit for medical encounter 
Sneezing Noticeable but does not 
interfere with daily 
activity Moderate discomfort that 
interferes with daily 
activity Significant discomfort; 
prevents daily activity 
Sinus pressure/pain Noticeable but does not 
interfere with daily 
activity Moderate discomfort that 
interferes with daily 
activity Significant discomfort that 
prevents daily activity or 
seeks medical care 
Sore/irritated throat Noticeable but does not 
interfere with eating or 
drinking Moderate discomfort that 
interferes with eating or 
drinking Significant discomfort that 
prevents eating or drinking 
or seeks medical care 
Cough Noticeable but does not 
interfere with daily 
activity or sleeping Frequent cough that 
interferes with daily 
activity or sleeping Prevents daily activity, 
prevents sleep, or seeks 
medical care 
Shortness of 
breath/wheezing Noticeable but does not 
interfere with daily 
activity Moderate discomfort that 
interferes with daily 
activity Significant discomfort/ 
prevents daily activity or 
seeks medical encounter 
Subjective Systemic Reactogenicity Grading 
Systemic (Subjective)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Fever c - oral d 100.4°F – 101.1°F 101.2°F – 102.0°F >102.0°F 
Fatigue (tiredness) No interference with daily 
activity Some interference 
with daily activity Significant interference, 
prevents daily activity 
Malaise (general 
unwell feeling) No interference with daily 
activity Some interference 
with daily activity Significant interference, 
prevents daily activity 
Myalgia (body 
aches/muscular pain) No interference with daily 
activity Some interference 
with daily activity Significant interference, 
prevents daily activity 
Arthralgia (joint pain) No interference with daily 
activity Some interference 
with daily activity Significant interference, 
prevents daily activity 
Headache No interference with daily 
activity Some interference 
with daily activity Significant interference, 
prevents daily activity 
Rash/hypersensitivity e Pruritus OR local rash Diffuse rash Diffuse rash with blisters or 
mouth ulcerations, 
anaphylaxis, or angioedema 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 71 Note: Grade 0 will be the classification if the obs ervation is less than a Grade 1. 
a In addition to grading the measured local reaction  at the greatest single diameter, the measurement s hould 
be recorded as a continuous variable. 
b Induration/swelling should be evaluated and graded  using the functional scale as well as the actual 
measurement. 
c A fever can be considered not related to the study  product if an alternative etiology can be document ed. 
d Subjects must not eat or drink anything hot or col d within 10 minutes prior to taking oral temperatur e. Oral 
temperature assessed on Day 1 prior to the first st udy vaccination will be considered as baseline. 
e Adapted from the Division of AIDS Table for Gradin g the Severity of Adult and Pediatric Adverse Event s 
Version 2. 2014.  
Source: DHHS 2007 
6.3.5.4  Assessing and Documenting Adverse Events 
Safety will be assessed by the frequency and severi ty of: 
1.  Serious AEs occurring from the time of vaccination through the end of the study. 
2.  Solicited reactogenicity – reactogenicity events oc curring from the time of each study 
vaccination through 7 days after each study vaccina tion: 
a.  Nasal/respiratory reactions including runny nose, s tuffy nose/congestion, nasal 
pain/irritation, epistaxis, sneezing, sinus pressur e/pain, sore/irritated throat, cough, 
and shortness of breath/wheezing. 
b.  Systemic reactions including fever, fatigue, malais e, myalgia, arthralgia, headache, 
and rash/hypersensitivity. 
c.  Local reactions – pain, tenderness, erythema/rednes s, induration/swelling  
3.  Unsolicited AEs – all AEs regardless of causality, will be collected for 28 days after 
each vaccination. Adverse events related to vaccina tion will be collected through 
Day 113. Between screening (signing of ICF) and Day  1, AEs will be collected if 
classifies as serious or if related to study proced ure or study involvement. Any AE that 
results in vaccination delay (eg, temporary exclusi ons due to acute illness or fever, or 
investigator determined medical condition) during s creening or during study conduct 
will also be recorded as an AE. Any newly identifie d potential AE of special interest 
will be followed through Day 254. 
4.  Any scheduled safety laboratory value that results in a Grade 3 toxicity score in the 
safety cohort will be recorded as an AE. Recording will be appropriate for either the 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 72 variable itself (eg, elevated creatine) or the cond ition which is diagnosed (eg, 
dehydration or chronic renal insufficiency). 
At every study visit, subjects will be asked a stan dard nonleading question to elicit any 
medically related changes in their well-being. They  will also be asked if they have been 
hospitalized, had any accidents, used any new medic ations, or changed concomitant 
medication regimens (both prescription and over-the -counter medications). 
In addition to subject observations, AEs identified  from any study data (eg, laboratory values, 
physical examination findings) or identified from r eview of other documents (eg, subject 
diaries) that are relevant to subject safety will b e documented on the AE page in the eCRF. 
6.3.5.5  Reporting Adverse Events 
All AEs reported or observed during the study will be recorded on the AE page in the eCRF. 
An AE can therefore be any unfavorable and unintend ed sign (including an abnormal 
laboratory finding), symptom, or disease temporally  associated with the use of a medicinal 
(investigational) product. The occurrence of an AE may come to the attention of study 
personnel during study visits and interviews of a s tudy recipient presenting for medical care, 
or upon review by a study monitor. 
Adverse events not meeting the protocol-defined cri teria for SAEs will be captured on the 
appropriate data collection form and eCRF. Informat ion to be collected for unsolicited 
nonserious AEs includes event description, date of onset, licensed study physician’s 
assessment of severity and relationship to study pr oduct and alternate etiology (if not related 
to study product), date of resolution of the event,  seriousness, and outcome. Adverse events 
occurring during the collection and reporting perio d will be documented appropriately 
regardless of relationship (as defined in Section 6.3.5.4 ). 
Any medical condition that is present at the time t hat the subject is screened will be 
considered as baseline and not reported as an AE; h owever, if the severity of any pre-existing 
medical condition increases, it will be recorded as  an AE. 
Adverse events must be graded for severity and asse ssed for relationship to study product. 
Adverse events characterized as intermittent requir e documentation of onset and duration of 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 73 each episode. The start and stop date of each repor ted AE will be recorded on the appropriate 
data collection form and eCRF. 
Adverse events resulting from concurrent illnesses,  reactions to concurrent illnesses, 
reactions to concurrent medications, or progression  of disease states must also be reported. 
All AEs will be followed to adequate resolution. Th e MedDRA will be used to code all AEs. 
6.3.5.6  Reporting Serious Adverse Events 
Any AE that meets SAE criteria ( Section 6.3.5.2 ) must be reported to the CRO immediately 
(ie, within 24 hours) after the time site personnel  first learn about the event. The contact 
information to be used for SAE reporting will be pr ovided to the CRO and the CRO will 
oversee the SAE reporting. 
6.3.5.7  Suspected Unexpected Serious Adverse Reactions and 
Nonserious Adverse Events of Special Interest 
The sponsor will promptly evaluate all SUSARs and n onserious AEs of special interest 
against cumulative product experience to identify a nd expeditiously communicate possible 
new safety findings to investigators, institutional  review boards (IRBs), and applicable health 
authorities based on applicable legislation. 
To determine reporting requirements for single AE c ases, the sponsor will assess the 
expectedness of these events using the following re ference documents: 
 study vaccination investigator's brochure 
The sponsor will compare the severity of each SUSAR  and the cumulative event frequency 
reported for the study with the severity and freque ncy reported in the applicable reference 
document. 
Reporting requirements will also be based on the in vestigator's assessment of causality and 
seriousness, with allowance for upgrading by the sp onsor as needed. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 74 6.3.5.8  Assessment of Severity 
The severity, or intensity, of an AE refers to the extent to which an AE affects the subject’s 
daily activities. The intensity of the AE will be r ated as mild, moderate, or severe using the 
following criteria: 
Mild 
(Grade 1): These events require minimal or no treatment and do  not interfere with the 
subject’s daily activities. 
Moderate 
(Grade 2): These events result in a low level of inconvenience  or concern with the 
therapeutic measures. Moderate events may cause som e interference with 
normal functioning. 
Severe 
(Grade 3): These events interrupt a subject’s usual daily acti vity and may require systemic 
drug therapy or other treatment. Severe events are usually incapacitating. 
 
Changes in the severity of an AE should be document ed to allow an assessment of the 
duration of the event at each level of intensity to  be performed. Adverse events characterized 
as intermittent require documentation of onset and duration of each episode. 
6.3.5.9  Assessment of Causality 
The investigator’s assessment of an AE’s relationsh ip to study vaccination is part of the 
documentation process, but it is not a factor in de termining what is or is not reported in the 
study. If there is any doubt as to whether a clinic al observation is an AE, the event should be 
reported. 
The relationship or association of the test article  in causing or contributing to the AE will be 
characterized using the following classification an d criteria: 
 Related – There is a reasonable possibility that th e study vaccination caused the AE. 
Reasonable possibility means that there is evidence  to suggest a causal relationship 
between the study vaccination and the AE. 
 Not Related – There is not a reasonable possibility  that the administration of the study 
vaccination caused the event. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 75 6.3.5.10  Follow-up of Subjects Reporting Adverse Events 
All AEs must be reported in detail on the appropria te page in the eCRF and followed to 
satisfactory resolution, until the investigator dee ms the event to be chronic or not clinically 
significant, or until the subject is considered to be stable. Adverse events will be collected, 
assessed, and followed through resolution based on Section 6.3.5.4.  Serious AEs will be 
collected, assessed, and followed through end of st udy or until satisfactory resolution or 
clinically stable. 
Resolution of an AE/SAE is defined as the return to  pretreatment status or stabilization of the 
condition with the expectation that it will remain chronic. 
If the investigator becomes aware of an acute febri le illness and the investigator decides to 
bring the subject in for an evaluation to determine  etiology, then the investigator, at their own 
discretion, can determine the specific testing that  should be performed. Follow-up 
procedures, evaluations, and outcomes will be recor ded on the appropriate data collection 
form. 
6.3.6  Immunogenicity Assessments 
At least 6 days prior to vaccination (during screen ing and on Day 78), and on Days 29, 113, 
169, and 254 a mucosal nasal secretion collection w ill be taken using a nasal secretion 
collection device for testing of mucosal antibodies  (S-IgA) to pertussis antigens. The 
mucosal nasal secretion collected at screening will  only be tested if the subject is randomized 
into the study unless consent is provided to use th e sample for assay development needs 
specific to this vaccine program. 
On Days 78 (after a mucosal collection is completed ), 92, 96, and 113 (after a mucosal 
collection is completed) a nasal secretion sample w ill be taken for pertussis culture. Any 
subject who tested positive for pertussis culture a t Day 113 will also have a nasal secretion 
sample taken for pertussis culture on Day 254.  
Blood samples will be taken on Days 1 (prior to pri mary vaccination), 29, 85 (prior to 
boosting vaccination), 113, 169, and 254 for testin g of serum pertussis antibodies (IgG and 
IgA ELISA) to pertussis antigens.  
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 76 A subset of no more than 60 subjects (randomly assi gned to the 10 9 CFU dose) will opt in to 
provide blood samples for PBMC harvesting on Days 1 , 8, and 92. 
The details on the handling, processing, and shippi ng of immunogenicity samples will be 
provided in the Laboratory Manual.  
6.4  Halting Rules 
Further enrollment and study vaccinations will be h alted (paused) for SMC 
review/recommendation if any of the following are r eported: 
 Any subject experiences ulceration, abscess, or nec rosis in the nose that is considered 
to be related to study product administration, thro ugh 28 days following the boosting 
vaccination. 
 Any subject experiences laryngospasm, bronchospasm,  or anaphylaxis within 1 day 
after administration of study vaccination that is c onsidered to be related to study 
vaccination. 
 Three or more subjects experience generalized urtic aria grade 3 or higher within 
3 days after administration of study vaccination th at is considered to be related to 
study vaccination. 
 Any subject experiences a study product-related SAE  from the time of the primary 
vaccination through the subject’s last study visit on Day 254. 
 Any subject experiences acute weakness of limbs and /or cranial nerve innervated 
muscles (description of potential signal of Guillai n-Barré syndrome) after 
administration of study vaccination, through 28 day s following the boosting 
vaccination. 
This study will also be halted for SMC review/recom mendation if, within 8 days after 
administration of each study vaccination, the follo wing occurs: 
 5% of subjects experience the same severe study pro duct-related subjective systemic, 
local, or mucosal reaction, for which the severity (grade) is corroborated by study 
personnel. 
Grading scales for solicited reactions are included  in Section 6.3.5.3 . 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 77 If any of the halting rules are met following any s ubject receipt of study vaccination, then 
this study will not continue with the remaining enr ollments or future vaccination without a 
review by and recommendation from the SMC to procee d. Vaccination windows will be 
adjusted for any such pause to allow subjects to re main within the expected schedule of 
events. All events that classify for halting rules will be entered as adverse events. 
ILiAD retains the authority to suspend additional e nrollment and study interventions or 
administration of study product during the entire s tudy, as applicable. 
6.5  Pregnancy 
Pregnancy is not regarded as an AE unless there is a suspicion that an investigational vaccine 
may have interfered with the effectiveness of a con traceptive medication. Any pregnancy that 
occurs during study participation must be reported using a clinical study pregnancy form. To 
ensure subject safety, each pregnancy must be repor ted to the sponsor, ILiAD 
Biotechnologies, within 2 weeks of learning of its occurrence. If pregnancy occurs further 
vaccination will be discontinued. The pregnancy mus t be followed-up to determine outcome 
(including spontaneous miscarriage, elective termin ation, normal birth, or congenital 
abnormality) and status of mother and child, even i f the subject was discontinued from the 
study. Pregnancy complications and elective termina tions for medical reasons must be 
reported as an AE or SAE. Spontaneous miscarriages must be reported as an SAE. 
Any pregnancy, brought to the investigator’s attent ion after the subject has completed the 
study, but occurring while the subject was in the s tudy, must be promptly reported to ILiAD 
Biotechnologies. 
6.6  Laboratory Analyses 
Any abnormal laboratory test results (hematology, c hemistry, or coagulation) resulting in a 
grade 3 or greater toxicity score which is associat ed with the scheduled safety cohort follow 
up testing must be entered as an adverse event and followed with retesting and observing for 
resolution. If an underlying disease or new conditi on is identified that accounts for the 
elevation than this should be documented as the adv erse event.  
Any clinically significant safety assessments that are associated with the underlying or new 
onset condition for which laboratory testing occurs  during the course of the study will not be 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 78 entered as adverse events per se, rather the new on set or worsening condition should be 
entered as judged by the investigator. 
6.7  Sample Collections 
Procedures for the handling and processing of biolo gical samples are provided in the 
Laboratory Manual or the Site Manual.  
The hematology, coagulation, and chemistry laborato ry analyses will be performed at a 
central laboratory. Laboratory data will be graded according to the FDA Toxicity Grading 
Scale (Table 13-2) and will be adjusted according t o local laboratory reference ranges. 
The samples collected for immunogenicity (B and T c ell) testing and pertussis culture will be 
stored in appropriate conditions as specified in th e Laboratory Manual until shipped for 
testing at a facility designated by the sponsor. 
Subjects will be asked to provide a signed informed  consent for the use of samples for further 
pertussis-specific testing or assay development. Al iquots of collected samples from this study 
may be retained for additional testing of antigens specific to B. pertussis  for a maximum of 
10 years (starting from the date at which the last subject had the last study visit), unless local 
rules, regulations, or guidelines require different  timeframes or different procedures, in 
accord with subject consent. Testing for colonizati on using B. pertussis  culture following the 
primary vaccination and post-boosting vaccination w ill also occur.  
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 79 7 Statistical and Analytical Plan 
The primary objectives of this study are to assess nasal mucosal immune response S-IgA 
following intranasal vaccination with BPZE1 (10 9 CFU) when used as a single (eg, prime) or 
2-dose (eg, prime + boost) series and reactogenicit y (all) and specific safety laboratory 
parameters (safety lead-in cohort only) following i ntranasal vaccination with BPZE1 (10 9 
CFU), in healthy volunteers 18 to 50 years of age. This study is designed as a randomized, 
placebo-controlled, observer-blinded clinical trial  evaluating the safety and immunogenicity 
of 1 or 2 doses of 10 9 CFU of BPZE1 delivered by intranasal VaxINator dev ice or Boostrix 
delivered by IM injection. To maintain the blind, p lacebo vaccination via IM and intranasal 
routes will be included. 
The primary database lock will occur on Day 113 and  all data collected through Day 113 will 
be included in the CSR and submitted to regulatory authorities. A subsequent longer-term 
safety follow-up, including longer-term persistence  of immune responses, will occur through 
Day 254. These data will be provided in an addendum  to the CSR. The clinical site study 
team directly participating in subject contact/care  will remain blinded to the treatment 
assignment during this extended safety follow up pe riod. All unblinded data analyses prior to 
primary database lock at Day 113 will be handled by  the unblinded team of statisticians and 
programmers. A strict firewall between the blinded and unblinded teams will be maintained 
during study conduct. 
This Phase 2b study is not designed to test a forma l null hypothesis. Rather, it is intended to 
obtain preliminary assessment of the safety and imm unogenicity induced by the BPZE1 
lyophilized vaccine in healthy adults. 
7.1  Primary Immunogenicity and Safety Endpoints 
Immunogenicity:  
 Mucosal seroconversion (nasal mucosal secretion sam pling) : Proportion of subjects 
who achieve seroconversion against at least 1 pertu ssis antigen (PT, FHA, PRN, FIM 
2/3, or BPZE1 whole cell extract) in nasal secretio ns on Day 29 or 113 (prime or prime 
+ boost). 
Mucosal seroconversion is defined as a 2-fold incre ase over the baseline value (collected 
during screening) or a 4-fold increase over the min imal limit of assay detection 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 80 (whenever the baseline value falls below the limits  of assay detection) for any of the 
pertussis-specific antibodies (S-IgA ELISA): PT, FH A, PRN, FIM 2/3, or BPZE1 whole 
cell extract). Seroconversion will be calculated ba sed on absolute titer response over 
baseline and  by standardizing pertussis-specific ELISA response s relative to 
non-pertussis-specific total nasal mucosal secretio n (eg, IgA). To be further defined 
during assay development and within the statistical  analysis plan. 
Mucosal baseline samples will be taken at the scree ning visit. 
Safety: 
 Solicited AEs (local, nasal/respiratory, and system ic reactogenicity events) for 7 days 
following each vaccination by severity score, durat ion, and peak intensity. Local 
reactogenicity will only be monitored following the  IM vaccination. 
 Safety laboratory results (serum chemistry, hematol ogy, coagulation) by FDA toxicity 
score (change from baseline or absolute toxicity sc ore as defined in Table 13-2) in the 
safety lead-in cohort at Day 8 following each vacci nation. In the case of no toxicity 
classification the score of 0 will be assigned. 
7.2  Secondary Immunogenicity and Safety Endpoints  
Systemic Immunogenicity (serum sampling [expressed separately for IgG, IgA, and 
IgG or IgA ELISA when possible): 
 Proportion of subjects who achieve seroconversion a gainst pertussis antigen (PT, FHA, 
PRN, FIM 2/3, or BPZE1 whole cell extract) over bas eline for: 
 At least 1 antigen on each  of the Days 29, 85, 113, 169, or 254 
 At least 1 antigen on any  of the Days 29, 85, 113, 169, or 254 
 At least any 1 antigen on all  Days 29, 85, 113, 169, or 254 
Systemic seroconversion is defined as a 2-fold incr ease over the baseline value or a 
4-fold increase over the minimal limit of assay det ection (whenever the baseline value 
falls below the limits of assay detection). Both Ig G and IgA ELISA will measure 
antibodies against the following pertussis-specific  antigens of PT, FHA, PRN, and FIM 
2/3, and IgG ELISA will measure antibodies against broader pertussis-specific antigens 
in BPZE1 whole cell extract. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 81 Serum baseline samples will be taken at Day 1 prior  to vaccination. 
 Proportion of subjects who achieve seroconversion ( IgG ELISA only) against BPZE1 
whole cell extract over baseline: 
 On either  Day 29 (prime) or 113 (boost) 
 On both  Days 29 (prime) and 113 (boost). 
 Proportion of subjects who achieve seroconversion a gainst the aP antigens PT, FHA, and 
PRN over baseline: 
 On either  Day 29 (prime) or 113 (boost) 
 On both  Days 29 (prime) or 113 (boost). 
 Proportion of subjects who achieve seroconversion a gainst 2 or more pertussis antigens 
(PT, FHA, PRN, FIM 2/3, and BPZE1 whole cell extrac t) over baseline: 
 On each  of the Days 29, 85, 113, 169, or 254 
 On any  of the Days 29, 85, 113, 169, or 254 
 At least  the same 2 antigens  on all  Days 29, 85, 113, 169, and 254. 
 Proportion of subjects who demonstrate boosting for  each pertussis antigen (PT, FHA, 
PRN, FIM 2/3, and BPZE1 whole cell extract) on  Day 113. Boost is defined as at least a 
2-fold increase from the pre-boost sample taken on Day 85. 
 The GMFR against each pertussis antigen (PT, FHA, P RN, FIM 2/3, and BPZE1 whole 
cell extract): 
 On Days 29, 85, 113, 169, and 254 over baseline  (Day 1) 
 On Days 113, 169, and 254 over pre-boost  (Day 85) 
 The maximum over baseline  on either Day 29 or 85 (post-priming response) 
 The maximum over pre-boost  (Day 85) on any of the Days 113, 169, or 254 
(post-boost response) 
 The maximum during  the study. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 82  The GMT against each pertussis antigen (PT, FHA, PR N, FIM 2/3, and BPZE1 whole 
cell extract): 
 On Days 29, 85, 113, 169, and 254 
 The maximum on Day 29 or 85 ( after priming  dose) 
 The maximum after Days 113, 169, or 254 ( after boosting  dose) 
 The maximum during  the study. 
Mucosal Immunogenicity S-IgA ELISA (nasal mucosal s ecretion sampling): 
 Proportion of subjects who achieve seroconversion a gainst any pertussis-specific antigen 
(PT, PRN, FHA, FIM 2/3, or BPZE1 whole cell extract ) over baseline: 
 At least 1 antigen on each  of the Days 29, 78, 113, 169, or 254 
 At least 1 antigen on any  of the Days 29, 78, 113, 169, or 254 
 At least any  1 antigen on all  Days 29, 78, 113, 169, and 254. 
 Proportion of subjects who achieve seroconversion a gainst BPZE1 whole cell extract 
over baseline: 
 On either  Day 29 (prime) or 113 (boost) 
 On both  Days 29 (prime) and 113 (boost). 
 Proportion of subjects who achieve seroconversion a gainst aP antigens PT, FHA, and 
PRN over baseline: 
 On either  Days 29 (prime) or 113 (boost) 
 On both  Days 29 (prime) and 113 (boost). 
 Proportion of subjects who achieve seroconversion f or any 2 or more pertussis antigens 
(PT, PRN, FHA, or BPZE1 whole cell extract) over ba seline: 
 On each  of Days 29, 78, 113, 169, or 254 
 On any  of Days 29, 78, 113, 169 or 254 
 At least the same 2 antigens  on all Days 29, 78, 113, 169, and 254. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 83  Proportion of subjects who demonstrate boosting aga inst each pertussis antigen (PT, 
FHA, PRN, FIM 2/3, and BPZE1 whole cell extract) on  Day 113. Boost is defined as at 
least a 2-fold increase from pre-boost sample taken  at Day 78.  
 The GMFR against each pertussis antigen (PT, FHA, P RN, FIM 2/3, and BPZE1 whole 
cell extract): 
 On Days 29, 78, 113, 169, and 254 over baseline  (Day 1) 
 On Days 113, 169, and 254 over pre-boost  (Day 78) 
 The maximum over baseline  on either Day 29 or 78 (post-priming response) 
 The maximum over pre-boost  (Day 78) on any of the Days 113, 169, or 254 
(post-boost response) 
 The maximum during  the study. 
 The GMT against each pertussis antigen (PT, FHA, PR N, FIM 2/3, and BPZE1 whole 
cell extract): 
 On Days 29, 78, 113, 169, and 254 
 The maximum on Days 29 or 78 ( after priming  dose) 
 The maximum after Days 113, 169, or 254 ( after boosting  dose) 
 The maximum during  the study. 
Colonization: 
 Proportion of subjects with positive B. pertussis  by bacterial culture of nasal sample 
collected on each day and on any day (Days 92, 96, and 113). 
 B. pertussis  colony counts on each day (Days 92, 96, and 113).  
 Number of subjects who remain culture positive for B. pertussis  at Days 78 (following 
priming) and 254 (following boost).  
Safety: 
 Unsolicited AEs (eg, treatment-emergent AEs, SAEs, and SUSARs) collected for 
28 days following each vaccination by MedDRA classi fication and severity score.  
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 84  Unsolicited AEs related to vaccination through Day 113 by MedDRA classification and 
severity score. 
 Serious AEs, through 6 months following the last va ccination (or until resolved or 
stable) by MedDRA classification, relatedness, and severity score. 
 Vital sign measurements with severity scoring immed iately following vaccination. 
7.3  Exploratory Endpoints 
 Cell-mediated (eg, B cell, CD4 T lymphocytes + T ce ll, CD8 T lymphocytes + T cell) 
responses (eg, cell staining, cytokine production) following stimulation of PBMCs 
collected at baseline, and 8 days post-vaccination (prime and boost) to pertussis-specific 
antigens. Results expressed both as absolute values  and fold over baseline (per specific 
assay characteristics). 
 Following the outcomes of the primary and secondary  analyses, additional exploratory 
endpoints may be tested for systemic or nasal mucos al immunogenicity (IgG or IgA) 
responses at any time point collected and not alrea dy performed in the primary or 
secondary analysis sets. 
 The GMT, expressed for serum IgG ELISA against teta nus and diphtheria on Days 29 
and 113. 
7.4  Sample Size Calculations 
A total of 300 subjects will be globally assigned a t 2:2:1:1 allocation ratio and receive 
BPZE1 intranasal administration with placebo IM or Boostrix IM with placebo intranasal 
administration on Day 1 and BPZE1 or placebo intran asal administration on Day 85 (See 
Section 5.2 ). This sample size is based on clinical considerat ions but not a statistical power 
analysis as the study does not test any formal null  hypothesis. Table 7-1 presents the width of 
95% CI for selected certain sample sizes under resp onse rate assumptions (defined based on 
nasal mucosal immunogenicity) between 50% and 90%. Calculations were performed using 
PASS v12. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 85 Table 7-1 95% Confidence Interval and Width for Sel ected Response Rate 
Assumptions for Relevant Treatment Arm Sample Sizes  
Response 
Rate (%) N = 50 N = 100 N = 200 N = 250 
CI (%) Width 
(%) CI (%) Width 
(%) CI (%) Width 
(%) CI (%) Width 
(%) 
50 35.5, 64.5 28.9 39.8, 60.2 20.3 42.9, 57.1 14.3 43.6, 56.4 12.7 
60 45.2, 73.6 28.4 49.7, 69.7 19.9 52.9, 66.8 14.0 53.6, 66.1 12.5 
70 55.4, 82.1 26.7 60.0, 78.8 18.7 63.1, 76.3 13.1 63.9, 75.6 11.7 
80 66.3, 90.0 23.7 70.8, 87.3 16.5 73.8, 85.3 11.5 74.5, 84.8 10.3 
90 78.2, 96.7 18.5 82.4, 95.1 12.7 85.0, 93.8 8.8 8 5.6, 93.4 7.8 
Abbreviation: N, sample size.  
Note: As described in the study design section, 200  subjects will receive a primary vaccination and 10 0 out 
of those 200 subjects will receive a boosting vacci nation. In addition, 50 out of 100 active control s ubjects 
will receive a BPZE1 boost.  
7.5  Analysis Sets 
The Safety Analysis Set will consist of all subject s who have received at least 1 dose of the 
study vaccine and have any safety data available. S ubjects will be classified according to the 
vaccine actually received. The primary safety analy sis will be done on this analysis set. 
The Intent to Treat Analysis Set will consist of al l subjects who have been randomized to the 
study. Subjects will be classified according to the  study group randomized. The data of 
subject disposition, demographics, and medical hist ory will be summarized on this analysis 
set. 
The Immunogenicity Analysis Set will include all th e Intent to Treat subjects who received 
the prime dose of the study vaccine(s) and have con tributed both pre- and at least 
1 post-prime vaccination sample (mucosal or serum i mmunogenicity testing, respectively) 
for which valid results were reported and who have not received any component of a licensed 
pertussis vaccine in the 5 years through Day 113 of  the study. Subjects will be classified 
according to the study vaccine received. For analys is of boosting, those subject who have 
received all vaccinations and have a pre- (Day 78 f or mucosal and Day 85 for serum) and a 
post-boost immune sample (Day 113) for which valid results were reported will be utilized. 
Additional testing for maximum response will be ass essed for those subjects who received all 
vaccinations and have both a baseline sample (scree ning or Day 1 depending on the sample 
type) and a sample at Day 113. Immune persistence w ill be assessed in those subjects who 
contribute to sampling at Days 169 and 254. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 86 The Per Protocol Analysis Set will include all subj ects in the Prime/Boost Immunogenicity 
Analysis Set, with the following exclusions: 
 Data from all available visits for subjects followi ng the receipt of unsuitable 
investigational product (either via dispensed/assig ned or delivered). 
 Data from all available visits for subjects found t o be ineligible at baseline per 
Protocol Version 6.0. 
 Data from all visits for subjects following the use  of major immune-modulators, 
immune suppressants, receipt of blood products, or use of forbidden nasal solutions 
(eg, sprays, washes, neti pot) from 30 days prior t o Day 1 through Day 113. 
 Data from all visits for subjects following clinica lly significant protocol deviations 
that can affect the efficacy (immunogenicity) resul ts. 
 Data from any visit that occurs substantially out o f window as defined by exceeding 
30 days past the visit window or the time point whe reby the follow-on visit should 
have occurred, whichever is most restrictive. Stand ard visit windows are described in 
schedule of events (Appendix 13.1).  
For analyses using the Per Protocol Analysis Set, s ubjects will be grouped based on study 
vaccines actually received. 
7.6  Description of Subgroups to be Analyzed 
Immunogenicity endpoints (seroconversion, GMT, and GMFR) will be summarized by 
baseline negative and positive status of various pe rtussis antibodies (eg, any subject positive 
for PT, PRN, FHA, or FIM 2/3). Other subgroup analy ses may be performed for selected 
factors, such as pertussis vaccination history, smo king status, or nasal spray use at study 
baseline or during the study. 
7.7  Statistical Analysis Methodology 
Statistical analysis will be performed using SAS so ftware Version 9.3 or later. Continuous 
variables will be summarized using the mean, 2-side d 95% CI of the mean, SD, median, 
minimum value, and maximum value. Categorical varia bles will be summarized using 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 87 frequency counts and percentages, as well as 2-side d 95% CI for proportions computed using 
Clopper-Pearson method. Graphics of reverse cumulat ive distribution of anti-pertussis 
antibody titers will be generated for Days 29 and 1 13. 
Where applicable, data analyses will be conducted f or the prime period (prior to boosting) 
and boost period (at or post-boosting).  
Data will be listed in data listings.  
Further details of the planned statistical analyses , methods, and data conventions are 
described in the statistical analysis plan. 
No formal hypothesis will be tested in this study. 
7.7.1  Analysis of Primary Immunogenicity Endpoint 
Summaries and analysis of immunogenicity data will be presented for the Immunogenicity 
and Per Protocol Analysis Set. For immunogenicity d ata in the prime period, subjects in the 
Prime Immunogenicity Analysis Set will be grouped i nto BPZE1 prime (A+B) and Boostrix 
prime (C+D) arms. For immunogenicity data in the bo ost period, subjects in the Boost 
Immunogenicity Analysis Set will be grouped to BPZE 1 prime with BPZE1 boost (A), 
BPZE1 prime with no boost (B), Boostrix prime with BPZE1 boost (C) and Boostrix prime 
with no boost (D). In addition, as multiple antigen s are being tested across vaccine 
combinations, all possible treatment group combinat ions will be displayed. For priming data 
analysis, the primary endpoint will be based on nas al mucosal immunogenicity change from 
screening, and for boost data analysis that will be  based on screening and Day 78 prior to 
boost vaccination. The Immunogenicity and Per Proto col Analysis Sets will be used for 
sensitivity analysis. 
The proportion and 95% CI of subjects who achieve s eroconversion at Day 29 for prime 
vaccination and Day 113 for boost vaccination will be analyzed. Seroconversion is defined as 
a 2-fold increase over the baseline value or a 4-fo ld increase over the minimal limit of assay 
detection in S-IgA ELISA from nasal secretions for any of the pertussis-specific antibodies 
(S-IgA ELISA): PT, FHA, PRN, FIM 2/3, or BPZE1 whol e cell extract). Baseline is defined 
as the value at screening.  
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 88 7.7.2  Analysis of Primary Safety Endpoint 
All summaries and analyses will be presented over a ll subjects and by treatment arm for 
prime and boost periods whenever possible. The trea tment arms are BPZE1 versus Boostrix 
in prime period. For boost period, treatment arms a re BPZE1 prime with BPZE1 boost (A), 
BPZE1 prime with no boost (B), Boostrix prime with BPZE1 boost (C), and Boostrix prime 
with no boost (D). The combination of A + C (receiv ed BPZE1 on Day 85) and B + D (did 
not receive BPZE1 on Day 85) will be combined when assessing short term reactogenicity 
and AEs through Day 28 post-boost. 
Solicited AEs will be summarized by severity for ea ch day after each study vaccination for 
7 days and as the maximum severity over all 7 days after each vaccination. Additionally, 
solicited AEs will be analyzed by taking the most s evere response over the follow-up period, 
dichotomizing into a binary variable (none versus m ild, moderate, or severe) to summarize 
the proportion (with exact 95% CIs) of subjects rep orting each symptom, any local, mucosal, 
or general systemic symptom. Summaries of solicited  AEs will be presented separately by 
treatment arm for the prime period and the boost pe riod when applicable as mentioned in the 
previous paragraph. Should any reactogenicity event  extend beyond 7 day post-vaccination 
and be clinically significant by toxicity grade of 1 or greater, than the event will be entered as 
an AE with the same start date as the reactogenicit y event and followed to resolution.  
Clinical safety laboratory test results for the saf ety lead-in cohort will be classified per FDA 
toxicity scoring system (Table 13-2) based on test value and change from baseline when 
applicable (as defined in Table 13-2). Counts and p ercentages of subjects by toxicity 
classifications and classification shift from basel ine will be presented in tabulations by 
treatment arm. The full cohort will have baseline s afety values expressed as mean/median 
with standard error per treatment group(s). 
7.7.3  Analysis of Secondary Immunogenicity Endpoint 
The secondary nasal mucosal  immunogenicity endpoints will be summarized by tre atment 
arm. Analyses will include the GMTs along with corr esponding 95% CIs and GMFRs from 
baseline at each time point and maximum titer or ra tio at any time point, as well as the 
proportion of subjects with seroconversion, defined  as a 2-fold increase in S-IgA over 
baseline or 4-fold over the minimal limit of assay detection at any time point and at each time 
point. The baseline refers to screening and Day 78 prior to boost vaccination. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 89 Systemic immune responses in terms of seroconversion of IgG and IgA antibody titers (PT, 
FHA, PRN, FIM 2/3, or BPZE1 whole cell extract for IgG only) will be summarized by 
treatment arm. Analyses will include the GMTs along  with corresponding 95% CIs and 
GMFR at each time point and maximum titer or ratio at any time point, as well as the 
proportion and 95% CI of subjects achieving serocon version (defined as 2-fold increase over 
baseline or 4-fold increase over the minimum limit of detection) at any time point and at each 
time point. 
Colonization data will be summarized by treatment a rm at available time points. Analysis 
will include dichotomized results (Yes/No) for B. pertussis  culture along with colony counts 
from Days 92 to 113 following vaccination with BPZE 1 or placebo. The effect of recent and 
post vaccination with BPZE1 on absolute colony coun ts and clearance of colonization will be 
assessed for this period. The analyses will include  proportion of subjects with positive B. 
pertussis  at Day 78 (prior to boosting vaccination) as well as Day 254 (end-of-study). 
7.7.4  Analyses of Efficacy Endpoint 
No clinical efficacy endpoint will be collected in this study other than immunological 
response. 
7.7.5  Analysis of Secondary Safety Endpoints 
Adverse events (eg, treatment-emergent AEs, SAEs, a nd SUSARs) will be coded by 
MedDRA for preferred term and system organ class. 
Serious AEs will be reported by detailed listings s howing the event description, MedDRA 
preferred term and system organ class, relevant dat es (study vaccinations and AEs), severity, 
relatedness, and outcome for each event. Any SAE at tributed to vaccination will be classified 
as a SUSAR. Nonserious unsolicited AEs will be summ arized as number and percentage of 
subjects reporting at least one event in each MedDR A preferred term and system organ class, 
and cross tabulated by severity and relationship to  study product.  
Measurements of vital signs will be statistically d escribed, and categorical severity scores of 
vital signs will be summarized in counts and percen tages of subjects by treatment arm. 
Change from baseline will be expressed where applic able. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 90 7.7.6  Other Analyses 
Summary statistics will be provided for exploratory  endpoints, demographics, medical 
history, study dose compliance, physical examinatio n, social history, and risk factor variables 
at baseline. Exploratory analysis will include test ing of T-cell responses using stimulated 
PBMCs for the subset of subjects at a later time po int. Tetanus and diphtheria testing (per 
validated ELISA) may occur at a later date and may include only selected subsets. Future 
assays developed for BPZE1 may also utilize samples  from this study for either development 
or testing at a future time. 
7.7.7  Interim Analyses 
A SMC will be convened by ILiAD Biotechnologies to review study progress and 
participant, clinical, safety, and reactogenicity d ata, as described after all doses in the safety 
lead-in cohort complete Day 8 following first (prim e) vaccination to allow the remainder of 
the subjects to be randomized. The SMC safety revie w must include at minimum 
demographic information, clinical laboratory values  (with toxicity grading), dosing 
compliance, reactogenicity (with toxicity grading),  and AE/SAEs (graded and attributed). 
Additional data may be requested by the SMC, and an  interim statistical report may be 
generated as deemed necessary and appropriate by IL iAD Biotechnologies. The SMC may 
receive data in aggregate and presented by treatmen t arm, including expected and observed 
rates of the expected AEs. The SMC will review grou ped data in the closed session only. The 
SMC will meet and review these data at scheduled ti me points or ad hoc as needed during 
this trial as defined in the SMC charter. As an out come of any meeting (after the safety 
lead-in cohort or with a safety pause), the SMC wil l make a recommendation as to the 
advisability of proceeding with study vaccinations (as applicable), and to continue, modify, 
or terminate this trial. The SMC will be provided w ith an executive summary of safety and 
immunogenicity results (graphic and written) for th e overall study. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 91 8 Data Quality Assurance 
The sponsor will perform quality control and assura nce checks on all clinical studies that it 
sponsors. Before enrolling any subjects in this stu dy, sponsor personnel and the investigator 
will review the protocol, the package inserts, inve stigator brochures, the eCRFs and 
instructions for their completion, the procedure fo r obtaining informed consent, and the 
procedure for reporting AEs and SAEs. A qualified r epresentative of the sponsor will monitor 
the conduct of the study by visiting the site and b y contacting the site by telephone and 
e-mail. During these site visits, information recor ded in the eCRFs will be verified against 
source documents. 
8.1  Data Management 
As part of the responsibilities assumed by particip ating in the study, the investigator agrees to 
maintain adequate case histories for the subjects t reated as part of the research under this 
protocol. The investigator agrees to maintain accur ate eCRFs and source documentation as 
part of the case histories. These source documents may include laboratory reports and subject 
diaries for reactogenicity reporting. 
Study site staff will enter subject data into a FDA -approved and auditable data management 
system. The analysis data populations will be a com bination of these data and data from other 
sources (eg, laboratory data). 
Clinical data management will be performed in accor dance with applicable PPD and/or 
ILiAD standards and data cleaning procedures to ens ure the integrity of the data, eg, 
removing errors and inconsistencies in the data. Ad verse event terms (including SAEs) will 
be coded using the MedDRA, an internal validated me dical dictionary, and concomitant 
medications will be coded using the WHO Drug Dictio nary. 
After final database lock, each clinical site will receive a compact disc read-only memory 
(CDROM) containing all of their site-specific eCRF data as entered into an FDA-approved 
and auditable data management system for the study,  including full discrepancy and audit 
history. Additionally, a CDROM copy of all of the s tudy site’s data from the study will be 
created and sent to the sponsor for storage. The CR O will maintain a duplicate CDROM copy 
for their records. In all cases, subject initials w ill not be collected or transmitted to the 
sponsor. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 92 9 Ethics 
9.1  Institutional Review Board 
Federal regulations and the International Council f or Harmonisation (ICH) guidelines require 
that approval be obtained from an IRB before partic ipation of human subjects in research 
studies. Before study onset, the protocol, informed  consent, advertisements to be used for the 
recruitment of study subjects, and any other writte n information regarding this study to be 
provided to the subject or the subject’s legal guar dian must be approved by the IRB. 
Documentation of all IRB approvals and of the IRB c ompliance with ICH harmonised 
tripartite guideline E6(R2): Good Clinical Practice  (GCP) will be maintained by the site and 
will be available for review by the sponsor or its designee. 
All IRB approvals should be signed by the IRB chair man or designee and must identify the 
IRB name and address, the clinical protocol by titl e or protocol number or both, and the date 
approval or a favorable opinion was granted. 
The investigator is responsible for providing writt en summaries of the progress and status of 
the study at intervals not exceeding 1 year or othe rwise specified by the IRB. The 
investigator must promptly supply the sponsor or it s designee, the IRB, and, where 
applicable, the institution, with written reports o n any changes significantly affecting the 
conduct of the study or increasing the risk to subj ects. 
9.2  Ethical Conduct of the Study 
The study will be performed in accordance with the ethical principles that have their origin in 
the Declaration of Helsinki, ICH GCP, the protocol,  and all applicable regulations. 
9.3  Subject Information and Consent 
A written informed consent in compliance with regul atory authority regulations US Title 21 
Code of Federal Regulations (CFR) Part 50 shall be obtained from each subject before 
entering the study or performing any unusual or non routine procedure that involves risk to 
the subject. An informed consent template may be pr ovided by the sponsor to investigative 
sites. If any institution-specific modifications to  study-related procedures are proposed or 
made by the site, the consent should be reviewed by  the sponsor or its designee or both 
before IRB submission. Once reviewed, the consent w ill be submitted by the investigator to 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 93 his or her IRB for review and approval before the s tart of the study. If the ICF is revised 
during the course of the study, all active particip ating subjects must sign the revised form. 
Before recruitment and enrollment, each prospective  subject or his or her legal guardian will 
be given a full explanation of the study and be all owed to read the approved ICF. Once the 
investigator is assured that the subject/legal guar dian understands the implications of 
participating in the study, the subject/legal guard ian will be asked to give consent to 
participate in the study by signing the ICF.  
The investigator shall retain the signed original I CF and give a copy of the signed original 
form to the subject or legal guardian. 
Subjects will also be asked to provide a signed inf ormed consent for the use of samples for 
further pertussis-specific testing or assay develop ment. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 94 10  Investigator’s Obligations 
The following administrative items are meant to gui de the investigator in the conduct of the 
study but may be subject to change based on industr y and government standard operating 
procedures, working practice documents, or guidelin es. Changes will be reported to the IRB 
but will not result in protocol amendments. 
10.1  Confidentiality 
All laboratory specimens, evaluation forms, reports , and other records will be identified in a 
manner designed to maintain subject confidentiality . All records will be kept in a secure 
storage area with limited access. Clinical informat ion will not be released without the written 
permission of the subject (or the subject’s legal g uardian), except as necessary for monitoring 
and auditing by the sponsor, its designee, the FDA,  or the IRB. 
The investigator and all employees and coworkers in volved with this study may not disclose 
or use for any purpose other than performance of th e study any data, record, or other 
unpublished, confidential information disclosed to those individuals for the purpose of the 
study. Prior written agreement from the sponsor or its designee must be obtained for the 
disclosure of any said confidential information to other parties. 
10.2  Financial Disclosure and Obligations 
Investigators and subinvestigators are required to provide financial disclosure information to 
allow the sponsor to submit the complete and accura te certification or disclosure statements 
required under 21 CFR 54. In addition, the investig ator and subinvestigator must provide to 
the sponsor a commitment to promptly update this in formation if any relevant changes occur 
during the course of the investigation and for 1 ye ar following the completion of the study. 
Neither the sponsor nor the CRO is financially resp onsible for further testing or treatment of 
any medical condition that may be detected during t he screening process. In addition, in the 
absence of specific arrangements, neither the spons or nor the CRO is financially responsible 
for further treatment of the subject’s disease. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 95 10.3  Investigator Documentation 
Prior to beginning the study, the investigator will  be asked to comply with ICH E6(R2) 
8.2 and Title 21 of the CFR by providing the follow ing essential documents, including but 
not limited to: 
 IRB approval 
 Original investigator-signed investigator agreement  page of the protocol 
 Form FDA 1572, fully executed, and all updates on a  new fully executed Form 
FDA 1572 
 Current (within 2 years) curriculum vitae for the i nvestigator and each subinvestigator 
listed on Form FDA 1572 
 Financial disclosure information to allow the spons or to submit complete and accurate 
certification or disclosure statements required und er 21 CFR 54. In addition, the 
investigators must provide to the sponsor a commitm ent to promptly update this 
information if any relevant changes occur during th e course of the investigation and for 
1 year after the completion of the study. 
 Executed clinical study agreement 
 Documentation of Federal Wide Assurance number and expiration date 
 IRB-approved informed consent, samples of site adve rtisements for recruitment for this 
study, and any other written information regarding this study that is to be provided to the 
subject or legal guardian 
 Site delegation log 
 Documentation of human subjects’ protection trainin g by all staff listed on the site 
delegation log 
 Laboratory certifications and normal ranges for any  local laboratories used by the site, in 
accordance with 42 CFR 493 
 Centers for Laboratory Improvement Amendments waive d on site urine pregnancy test 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 96 10.4  Study Conduct 
The investigator agrees that the study will be cond ucted according to the principles of ICH 
E6(R2) and 21 CFR 312. The investigator will conduc t all aspects of this study in accordance 
with all national, state, and local laws or regulat ions. Study information from this protocol 
will be posted on publicly available clinical trial  registers before enrollment of subjects 
begins. 
10.5  Adherence to Protocol 
The investigator agrees to conduct the study as out lined in this protocol in accordance with 
ICH E6(R2) and 21 CFR 312 and all applicable guidel ines and regulations. 
10.6  Adverse Events and Study Report Requirements 
By participating in this study, the investigator ag rees to submit reports of SAEs according to 
the time line and method outlined in the protocol. In addition, the investigator agrees to 
submit annual reports to the study site IRB as appr opriate. 
10.7  Investigator’s Final Report 
Upon completion of the study, the investigator, whe re applicable, should inform the 
institution; the investigator/institution should pr ovide the IRB with a summary of the study’s 
outcome and the sponsor and regulatory authority(ie s) with any reports required. 
10.8  Records Retention 
Essential documents should be retained until at lea st 2 years after the last approval of a 
marketing application in an ICH region and until th ere are no pending or contemplated 
marketing applications in an ICH region or at least  2 years have elapsed since the formal 
discontinuation of clinical development of the inve stigational product, as described in 
21 CFR 312.62. These documents should be retained f or a longer period, however, if required 
by the applicable regulatory requirements or by an agreement with the sponsor. It is the 
responsibility of the sponsor to inform the investi gator/institution as to when these 
documents no longer need to be retained. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 97 10.9  Publications 
After completion of the study, the data may be cons idered for reporting at a scientific 
meeting or for publication in a scientific journal.  In these cases, the sponsor will be 
responsible for these activities to determine how t he manuscript is written and edited, the 
number and order of authors, the publication to whi ch it will be submitted, and other related 
issues. The sponsor has final approval authority ov er all such issues. 
Data are the property of the sponsor and cannot be published without prior authorization 
from the sponsor, but data and publication thereof will not be unduly withheld. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 98 11  Study Management 
The administrative structure will include an unblin ded biostatistics team (statisticians and 
programmers). 
11.1  Monitoring 
11.1.1  External Data Monitoring Committee 
11.1.1.1  Safety Monitoring Committee 
Safety oversight will be conducted by a SMC that is  an independent group of experts that 
monitors subject safety and advises ILiAD Biotechno logies. The SMC members will be 
separate and independent of study personnel partici pating in this study and should not have 
scientific, financial, or other conflict of interes t related to this study. The SMC will consist of 
members with appropriate expertise to contribute to  the interpretation of the data from this 
study. 
The SMC will review study progress and participant,  clinical, safety, and reactogenicity data 
at the following time points: 
 After the subjects in the entire safety lead-in coh ort (both dose levels) have completed 
Day 8 (Visit 2). The SMC will review all safety dat a through Day 8 (reactogenicity 
and safety laboratory results) and any AEs which ha ve occurred since study initiation. 
 Ad hoc when a halting rule is met, for immediate co ncerns regarding observations 
during this study, or as needed. 
The SMC will operate under the rules of an ILiAD Bi otechnologies-approved charter that 
will be approved at the organizational meeting of t he SMC. At this time, each data element 
that the SMC needs to assess will be clearly define d. Procedures for SMC reviews/meetings 
will be defined in the charter. The SMC will review  applicable data to include, but not 
limited to, study progress and participant, clinica l, safety, and reactogenicity data. Reports 
may include enrollment and demographic information,  medical history, concomitant 
medications, physical assessments, and solicited an d unsolicited AE/SAEs. Additional data 
may be requested by the SMC, and interim statistica l reports may be generated as deemed 
necessary and appropriate by ILiAD Biotechnologies.  The SMC may receive data in 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 99 aggregate and presented by treatment arm. The SMC m ay also be provided with expected and 
observed rates of the expected AEs in an unblinded fashion and may request the treatment 
assignment be unblinded for an individual subject i f required for safety assessment.  
The SMC will review grouped and unblinded data in t he closed session only. The SMC will 
meet and review these data at scheduled time points  or ad hoc as needed during this study as 
defined in the SMC charter. As an outcome of each r eview/meeting, the SMC will make a 
recommendation as to the advisability of proceeding  with study vaccinations (as applicable), 
and to continue, modify, or terminate this study. 
ILiAD Biotechnologies or the SMC chair may convene the SMC on an ad hoc  basis 
according to protocol criteria or if there are imme diate concerns regarding observations 
during the course of the study. The ILiAD Biotechno logies medical monitor is empowered to 
stop enrollment and study vaccinations if AEs that meet the halting criteria are reported. The 
ILiAD Biotechnologies/CRO assigned medical monitor will be responsible for reviewing 
SAEs in real time. The SMC will review SAEs on a re gular basis and ad hoc during the 
study. 
11.1.2  Monitoring of the Study 
The clinical monitor, as a representative of the sp onsor, has the obligation to follow the study 
closely. In doing so, the monitor will visit the in vestigator and study site at periodic intervals, 
in addition to maintaining necessary telephone and letter contact. The monitor will maintain 
current personal knowledge of the study through obs ervation, review of study records and 
source documentation, and discussion of the conduct  of the study with the investigator and 
personnel. 
All aspects of the study will be carefully monitore d, by the sponsor or its designee, for 
compliance with applicable government regulation wi th respect to current GCP and current 
standard operating procedures. 
11.1.3  Inspection of Records 
Investigators and institutions involved in the stud y will permit study-related monitoring, 
audits, IRB review, and regulatory inspections by p roviding direct access to all study records. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 100 In the event of an audit, the investigator agrees t o allow the sponsor, representatives of the 
sponsor, or a regulatory agency (eg, FDA) access to  all study records. 
The investigator should promptly notify the sponsor  and the CRO of any audits scheduled by 
any regulatory authorities and promptly forward cop ies of any audit reports received to the 
sponsor. 
11.2  Management of Protocol Amendments and Deviations 
11.2.1  Modification of the Protocol 
Any changes in this research activity, except those  necessary to remove an apparent, 
immediate hazard to the subject, must be reviewed a nd approved by the sponsor or its 
designee. Amendments to the protocol must be approv ed by the IRB before subjects can be 
enrolled into an amended protocol. Letters of amend ment or clarification do not need to be 
approved by the IRB. 
11.2.2  Protocol Deviations 
The investigator or designee must document and expl ain in the subject’s source 
documentation any deviation from the approved proto col. The investigator may implement a 
deviation from, or a change of, the protocol to eli minate an immediate hazard to study 
subjects without prior IRB approval. As soon as pos sible after such an occurrence, the 
implemented deviation or change, the reasons for it , and any proposed protocol amendments 
should be submitted to the IRB for review and appro val, to the sponsor for agreement, and to 
the regulatory authorities, if required. 
A deviation from the protocol is an unintended or u nanticipated departure from the 
procedures or processes approved by the sponsor and  the IRB and agreed to by the 
investigator. A significant deviation occurs when t here is nonadherence to the protocol by the 
subject or investigator that results in a significa nt, additional risk to the subject. Significant 
deviations can include nonadherence to inclusion or  exclusion criteria, or nonadherence to 
FDA regulations or ICH GCP guidelines, and will lea d to the subject being withdrawn from 
the study ( Section 4.2 ). 
Protocol deviations will be documented by the clini cal monitor throughout the course of 
monitoring visits. Investigators will be notified i n writing by the monitor of deviations. The 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 101 IRB should be notified of all significant protocol deviations in a timely manner, as defined by 
the IRB. 
11.3  Study Termination 
Although ILiAD Biotechnologies has every intention of completing the study, ILiAD 
Biotechnologies reserves the right to discontinue t he study at any time for clinical or 
administrative reasons. 
The end of the study is defined as the date on whic h the last subject completes Visit 9 
(end-of-study visit) (Table 13-1). 
11.4  Final Report 
Whether the study is completed or prematurely termi nated, the sponsor will ensure that the 
CSRs are prepared and provided to the regulatory ag ency(ies) as required by the applicable 
regulatory requirement(s). The sponsor will also en sure that the CSRs in marketing 
applications meet the standards of the ICH harmonis ed tripartite guideline E3: Structure and 
content of CSRs.  
The primary database lock will occur at Day 113, an d all data collected through Day 113 will 
be included in the CSR and submitted to regulatory authorities. A subsequent longer-term 
safety follow-up, including longer-term persistence  of immune responses, will occur through 
Day 254. These data will be provided, following a s econd database lock, in an addendum to 
the CSR. Subjects will return to the clinical site on Day 254 (±15 days) for end-of-study 
procedures. 
Where required by applicable regulatory requirement s, an investigator signatory will be 
identified for the approval of the CSR. The investi gator will be provided reasonable access to 
statistical tables, figures, and relevant reports a nd will have the opportunity to review the 
complete study results. 
Upon completion of the CSR, the sponsor will provid e the investigator with the full summary 
of the study results. The investigator is encourage d to share the summary results with the 
study subjects, as appropriate. The study results w ill be posted on publicly available clinical 
trial registers. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 102 12  Reference List 
Althouse BM, Scarpino SV. Asymptomatic transmission  and the resurgence of Bordetella 
pertussis . BMC Med. 2015;13:146. 
Department of Health and Human Services (DHHS), Foo d and Drug Administration, Center 
for Biologics Evaluation and Research (US). Guidanc e for industry: Toxicity grading for 
healthy adult and adolescent volunteers enrolled in  preventive vaccine clinical trials. 
September 2007 [cited 2017 Nov 29]. Available from:  https://www.gpo.gov/fdsys/pkg/FR-
2007-09-27/pdf/E7-19155.pdf  
Division of AIDS (DAIDS), National Institute of All ergy and Infectious Diseases, National 
Institutes of Health, US Department of Health and H uman Services. Division of AIDS 
(DAIDS) table for grading the severity of adult and  pediatric adverse events. July 2017 [cited 
2019 May 10]. Available from: 
https://rsc.niaid.nih.gov/sites/default/files/daids gradingcorrectedv21.pdf 
Feunou PF, Ismaili J, Debrie AS, et al. Genetic sta bility of the live attenuated Bordetella 
pertussis vaccine candidate BPZE1. Vaccine. 2008;26(45):5722- 7. 
Feunou PF, Mielcarek N, Locht C. Reciprocal interfe rence of maternal and infant 
immunization in protection against pertussis. Vacci ne. 2016;34(8):1062-9. 
Headache classification committee of the internatio nal headache society (IHS), The 
international classification of headache disorders (ICHD-3), 3rd edition. Cephalalgia. 
2018;38(1):1-211. 
ILiAD Biotechnologies. BPZE1. Investigator’s brochu re, 0.42 ed. Weston (FL); 2017. 44 p. 
Locht C, Papin JF, Lecher S, et al. Live attenuated  pertussis vaccine BPZE1 protects baboons 
against Bordetella pertussis disease and infection. J Infect Dis. 2017;216(1):11 7-24. 
Mielcarek N, Debrie AS, Maheiux S, et al. Dose resp onse of attenuated Bordetella pertussis  
BPZE1-induced protection in mice. Clin Vaccine Immu nol. 2010;17(3):317-24. 
Mielcarek N, Debrie AS, Raze D, et al. Live attenua ted B. pertussis  as a single-dose nasal 
vaccine against whooping cough. PLoS Pathog. 2006;2 (7):e65. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 103 National Asthma Education and Prevention Program Ex pert Panel Report 3 (EPR-3), 
National Institutes of Health, US Department of Hea lth and Human Services, National Heart, 
Lung, and Blood Institute. Guidelines for the diagn osis and management of asthma. October 
2007 [cited 2019 May 10]. Available from: 
https://www.nhlbi.nih.gov/files/docs/guidelines/ast hsumm.pdf 
Skerry CM, Cassidy JP, English K, et al. A live att enuated Bordetella pertussis  candidate 
vaccine does not cause disseminating infection in g amma interferon receptor knockout mice. 
Clin Vaccine Immunol. 2009;16(9):1344-51. 
Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertu ssis vaccines protect against disease 
but fail to prevent infection and transmission in a  nonhuman primate model. Proc Natl Acad 
Sci USA. 2014;111(2):787-92. 
Wearing HJ, Rohani P. Estimating the duration of pe rtussis immunity using epidemiological 
signatures. PLoS Pathog. 2009;5(10):e1000647. 
Yeung KHT, Duclos P, Nelson EAS, et al. An update o f the global burden of pertussis in 
children younger than 5 years: a modelling study. L ancet Infect Dis. 2017;17(9):974-80. 
ILiAD Biotechnologies  BPZE1  
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 104 13  Appendices 
13.1  Appendix: Schedule of Events 
 
ILiAD BiotechnologiesBPZE1 BPZE1 
Protocol No.: IB-200P Clinical Study Protocol Amendment 5 
 
Confidential Page 105 Table 13-1 Schedule of Events 
Procedure Screening Treatment Period 
Study visit  0 1 2 3 4 5 6 7 8 9 10 a 
Days relative to most recent vaccination –30 to 0 1  8 29 78 85/1 8 12 29 85 169 
Days relative to first vaccination b –30 to 0 1 8 29 78 85 92 96 113 169 254 
Window allowance 30 0 +3 +7 -7 +10 +2 +/-2 +7 -7 ±1 5 
Informed consent X           
Inclusion/exclusion criteria X X c    X c      
Demographic and baseline data d X           
Medical history e X X c    X c      
Medication f X X X X X X X X X Xg X g 
Serology h X           
Urine drug screen X           
Physical examination i X X j X X  X j X X X   
Vital sign measurements X X k X X  X k X X X   
Safety laboratory tests for enrollment l X           
Safety laboratory tests for safety cohort m X  X   X n X     
Urine pregnancy test (female subjects of childbeari ng 
potential)  X X n    X n      
Randomization  X          
Vaccination o  X    X      
Subject diary dispensing p  X    X      
Subject diary reviewed q   X    X     
Reactogenicity - post-vaccination  X r X s   X r X s     
ILiAD BiotechnologiesBPZE1 BPZE1 
Protocol No.: IB-200P Clinical Study Protocol Amendment 5 
 
Confidential Page 106 Procedure Screening Treatment Period 
Study visit  0 1 2 3 4 5 6 7 8 9 10 a 
Days relative to most recent vaccination –30 to 0 1  8 29 78 85/1 8 12 29 85 169 
Days relative to first vaccination b –30 to 0 1 8 29 78 85 92 96 113 169 254 
Window allowance 30 0 +3 +7 -7 +10 +2 +/-2 +7 -7 ±1 5 
Immunogenicity laboratory tests for serum pertussis  
IgG and IgA ELISA  X n  X  X n   X X X 
Mucosal pertussis nasal antibody testing (S-IgA ELISA) – nasal absorption device 
t X u   X X    X X X 
Nasal collection for B. pertussis colonization     X v  X X X v  Xw 
PBMC for cellular immunity (subset of no more than 60 subjects)   X X    X     
Collection of serious adverse events and adverse events of special interest only 
 x          X X 
Adverse events x y  X X X X X X X X   
End-of-study form completion            X 
Abbreviations: ELISA, enzyme-linked immunosorbent a ssay; Ig, immunoglobulin; PBMC, peripheral blood mo nonuclear cell; S-IgA, secretory 
immunoglobulin A. 
a End-of-study Visit. 
b Days relative to vaccination are only estimates as the window allowance is not inclusive. Should a stu dy pause occur than visits/windows will be adjusted  to 
allow for subjects to continue without protocol dev iation. Visit schedule following the boosting vacci nation is calculated relative to the day the boosti ng 
vaccination was received. 
c Inclusion/exclusion criteria and medical history wi ll be reviewed and updated on Day 1 and Day 85 with  specific vaccination exclusions applied.  
d Including date of birth (day, month, and year), se x, race, ethnicity, weight, height, and body mass i ndex (derived). 
e Including prior and concomitant medical conditions , surgeries, and significant procedures. 
f Concomitant medications include all medications (i ncluding vaccines) taken by the subject from the ti me of signing the informed consent through 28 days 
after the boosting vaccination (or through early te rmination visit if prior to that time).  
g Only medications associated with serious adverse e vents. 
h Serology testing will include hepatitis B, hepatit is C, and human immunodeficiency virus.  
ILiAD BiotechnologiesBPZE1 BPZE1 
Protocol No.: IB-200P Clinical Study Protocol Amendment 5 
 
Confidential Page 107 i Full physical examination at screening; symptom-di rected (targeted) physical examination at all other  scheduled time points. Interim physical examinatio ns 
will be performed at the discretion of the investig ator, if necessary. Height and weight will be measu red at screening only.  
j On Day 1 (Visit 1) and 85 (Visit 5), targeted sympt om-directed physical examination will be performed before vaccine administration. 
k On Day 1 (Visit 1) and 85 (Visit 5), vital sign me asurements will be collected once before vaccine ad ministration and at 60 minutes (±15 minutes) after 
vaccine administration (before subjects are dischar ged). 
l Safety laboratory testing for safety cohort includ e (Table 13-2) hemoglobin, white blood count with d ifferential, platelet count, sodium, potassium, ran dom 
glucose, blood urea nitrogen, creatinine, calcium, albumin, total protein, bilirubin, alanine aminotra nsferase, aspartate aminotransferase, prothrombin t ime, 
and partial thromboplastin time. See Table 13-2 for  specific laboratory tests to utilize for exclusion  for the full cohort (kidney, hepatic, and 
hematology/coagulation only). Laboratory testing ma y be repeated once during the 30-day screening peri od if specific values used for exclusion criteria 
exceed toxicity Grade 1, with the last value being the value of record. 
m The first 48 subjects randomly assigned will be des ignated the safety lead-in cohort and safety labora tory testing will be performed in this subset beyon d the 
screening visit. Should any laboratory value result  in a grade 3 or greater toxicity score this lab mu st be entered as an adverse event and followed with  
retesting and observing for resolution or new clini cal baseline  
n Performed prior to vaccination.  
 Subjects will be randomly assigned as per Table 3- 1. 
p All subjects will record reactogenicity in the dai ly subject diary starting on the same day of the pr ime (Day 1) and boosting (Day 85) vaccinations and 
for additional days (not counting vaccination day). 
q The clinical staff will review the information fro m the subject diary with the subjects on Days 8 and  92. Toxicity grading will be applied by investigat or for 
all subject recorded reactogenicity on Days 1 throu gh 8. Should any reactogenicity event extend beyond  7 days post vaccination and be clinically signific ant 
by toxicity grade 1 or greater, then it will be ent ered as an AE with the same start date as the react ogenicity event and followed to resolution.  
r Reactogenicity will be collected on Day 1 (Visit 1 ) and 85 (Visit 5) at 60 minutes (±15 minutes) afte r dose administration (before subjects are discharg ed).  
s To be collected from day of vaccination through ad ditional 7 days post-vaccination by subject.  
t Must occur at least 6 days prior to intranasal vac cination. If a subject fails to return for Day 78 ( Visit 4) than nasal sampling for colonization shoul d occur on 
Day 85 (Visit 5) AFTER mucosal sampling has been pe rformed but PRIOR to nasal vaccination (and there m ust be a 60 minute window between nasal 
aspiration and vaccination).  
u Collected but only tested within the trial if the subject is randomly assigned into the study. Sample s may be used per subject consenting for additional  
product development needs. 
v To be collected after mucosal pertussis nasal antib ody collection. 
w Only in subjects who tested positive by pertussis c ulture at Day 113. Any subject who remains positive  to pertussis on Day 254 will be provided a short 
course of azithromycin. Should a subject be allergi c to azithromycin, an appropriate antibiotic will b e substituted that has effectiveness against B. pertussis . 
x At the discretion of the investigator a urine drug screen may be performed on any subject who experien ces an adverse event. 
y All adverse events will be collected 28 days after each vaccination. Adverse events related to vaccina tion will be collected through Day 113. 
ILiAD Biotechnologies BPZE1 
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 108 13.2  Appendix: FDA Table for Laboratory Grading 
Table 13-2 Laboratory Abnormalities 
Serum a Mild (Grade 1) Moderate 
(Grade 2) Severe 
(Grade 3) Potentially Life 
Threatening 
(Grade 4) b 
Sodium – hyponatremia (mEq/L)  132-134 130-131 125- 129 < 125 
Sodium – hypernatremia (mEq/L) 144-145 146-147 148- 150 > 150 
Potassium – hyperkalemia 
(mEq/L) 5.1-5.2 5.3-5.4 5.5-5.6 > 5.6 
Potassium – hypokalemia 
(mEq/L) 3.5-3.6 3.3-3.4 3.1-3.2 < 3.1 
Glucose – hyperglycemia  
Random (mg/dL)   
110-125  
126-200  
> 200 Insulin 
requirements or 
hyperosmolar 
coma 
Blood Urea Nitrogen (mg/dL)  23-26 27-31 > 31 Requires 
dialysis 
Creatinine (mg/dL)* 1.5-1.7 1.8-2.0 2.1-2.5 > 2.5 or requires 
dialysis 
Calcium – hypocalcemia (mg/dL) 8.0-8.4 7.5-7.9 7.0- 7.4 < 7.0 
Calcium – hypercalcemia (mg/dL) 10.5-11.0 11.1-11.5  11.6-12.0 > 12.0 
Albumin – hypoalbuminemia 
(g/dL)  2.8-3.1 2.5-2.7 < 2.5 -- 
Total Protein – hypoproteinemia 
(g/dL)  5.5-6.0 5.0-5.4 <5.0 -- 
Liver Function Tests – ALT, AST 
increase by factor* 1.1-2.5 × ULN 2.6-5.0 × ULN 5.1-10 × ULN > 10 × ULN 
Bilirubin – when accompanied by 
any increase in liver function test 
increase by factor* 1.1-1.25 × ULN 1.26-1.5 × ULN 1.51-1.75 × ULN > 1.75 × ULN 
Bilirubin – when liver function 
test is normal; increase by factor* 1.1-1.5 × ULN 1.6-2.0 × ULN 2.0-3.0 × ULN > 3.0 × ULN 
Hematology a Mild (Grade 1) Moderate 
(Grade 2) Severe (Grade 3) Potentially Life 
Threatening 
(Grade 4) b 
Hemoglobin (Female) (gm/dL)* 11.0-12.0 9.5-10.9 8.0-9.4 < 8.0 
Hemoglobin (Female) change 
from baseline value (gm/dL) Any 
decrease - 1.5 1.6-2.0 2.1-5.0 > 5.0 
Hemoglobin (Male) (gm/dL)* 12.5-13.5 10.5-12.4 8.5-10.4 < 8.5 
ILiAD Biotechnologies BPZE1 
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 109 Hemoglobin (Male) change from 
baseline value (gm/dL) Any 
decrease - 1.5 1.6-2.0 2.1-5.0 > 5.0 
WBC Increase (cell/mm 3)* 10,800-15,000 15,001-20,000 20,001-25,000 > 25,000 
WBC Decrease (cell/mm 3)* 2,500-3,500 1,500-2,499 1,000-1,499 < 1,000 
Platelets Decreased - cell/mm 3* 125,000 – 
140,000 100,000 – 
124,000 25,000 – 99,000 < 25,000 
Prothrombin time – increase by 
factor* 1.0-1.10 × ULN 1.11-1.20 × 
ULN 1.21-1.25 × ULN > 1.25 × ULN 
partial thromboplastin time – 
increase by factor * 1.0-1.2 × ULN 1.21-1.4 × ULN 1.41-1.5 × ULN > 1.5 × ULN 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of nor mal; 
WBC, white blood cell. 
*Screening labs with toxicity scores greater than 1  are exclusion criteria for the full cohort only (g reyed line 
items).  
All safety labs listed in Table 13-2 with a toxicit y score greater than 1 are exclusion criteria for t he safety 
cohort. 
a The laboratory values provided in the tables serve  as guidelines and are dependent upon institutional  
normal parameters. Institutional normal reference r anges should be provided to demonstrate that they a re 
appropriate.  
b The clinical signs or symptoms associated with lab oratory abnormalities might result in characterizat ion of 
the laboratory abnormalities as Potentially Life Th reatening (Grade 4). For example, a low sodium valu e 
that falls within a grade 3 parameter (125-129 mE/L ) should be recorded as a grade 4 hyponatremia even t if 
the subject had a new seizure associated with the l ow sodium value. 
Source: DHHS 2007 
  
ILiAD Biotechnologies BPZE1 
Protocol No: IB-200P Clinical Study Protocol Amendm ent 5 
 
Confidential Page 110 13.3  Appendix: FDA Table for Vital Sign Grading 
Table 13-3 Vital Sign Abnormality 
Vital Signs a  Mild 
(Grade 1)  Moderate 
(Grade 2)  Severe 
(Grade 3)  Potentially Life  
Threatening  
(Grade 4)  
Fever (°F) b 100.4 – 101.1  101.2 – 102.0  102.1 – 104  >104  
Tachycardia (beats per 
minute)  101 – 115  116 – 130  >130  Emergency room visit or   
hospitalization for arrhythmia  
Bradycardia (beats per  
minute) c 50 – 54  45 – 49  <45  ER visit or hospitalization for  
arrhythmia  
Hypertension (systolic)  
(mm Hg) 141 – 150  151 – 155  >155  ER visit or hospitaliza tion for  
malignant hypertension 
Hypertension (diastolic) 
(mm Hg)  91 – 95  96 – 100  >100  ER visit or hospitalizatio n for  
malignant hypertension  
Hypotension (systolic)  
(mm Hg)  85 – 89  80 – 84  <80  ER visit or hospitalization for 
hypotensive shock  
Note: Grade 0 will be the classification if the obs ervation is less than a Grade 1. Respiratory rate w as removed 
from the FDA table for vital sign grading as this i s not a parameter being measured in this study. 
a.  Subject should be at rest for all vital sign measur ements.  
b.  Oral temperature; no recent hot or cold beverages o r smoking.  
c.  When resting heart rate is between 60 to 100 beats per minute. Use clinical judgement when characteriz ing 
bradycardia among some healthy subject populations,  for example, conditioned athletes. 
Source: DHHS 2007. 
 
 
 
 
 
 
 
 
 
 